{"gene":"CNR2","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1993,"finding":"CNR2 (CB2) was cloned from macrophages in the marginal zone of spleen; it encodes a G-protein-coupled receptor for cannabinoids that is expressed in the periphery (macrophages/spleen) but not in the brain, establishing it as the peripheral cannabinoid receptor distinct from the CNS-expressed CB1.","method":"Molecular cloning, receptor expression in heterologous cells, radioligand binding","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper, foundational, >3900 citations, multiple orthogonal methods","pmids":["7689702"],"is_preprint":false},{"year":1995,"finding":"CB2 mRNA is expressed at 10–100-fold higher levels in immune tissues than CB1, with rank order B-cells > NK cells >> monocytes > PMNs > T8 > T4 cells; CB2 protein was confirmed by immunohistology restricted to B-lymphocyte-enriched mantle zones of secondary follicles in tonsil.","method":"Quantitative RT-PCR, Northern blot, immunohistochemistry on human immune tissues and leukocyte subpopulations","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, foundational distribution paper","pmids":["7556170"],"is_preprint":false},{"year":1996,"finding":"Mouse CB2 (mCB2) was cloned from a splenocyte cDNA library; both hCB2 and mCB2 mediate agonist-stimulated inhibition of forskolin-induced cAMP production in stably transfected CHO cells, demonstrating Gi-coupled adenylyl cyclase inhibition as the primary effector mechanism.","method":"Molecular cloning, cAMP assay in transfected CHO cells, radioligand binding","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — in vitro functional reconstitution with cloned receptor, replicated across species","pmids":["8679694"],"is_preprint":false},{"year":1997,"finding":"CB2 is coupled to Gi-proteins; its effector systems include inhibition of adenylyl cyclase and modulation of ion channels; CB2 is present in peripheral tissues and immune cells but absent from the CNS under normal conditions.","method":"Pharmacological review integrating binding assays, functional effector studies, and tissue distribution data","journal":"Pharmacology & therapeutics","confidence":"High","confidence_rationale":"Tier 2 — comprehensive integration of multiple experimental datasets, >1100 citations","pmids":["9336020"],"is_preprint":false},{"year":1998,"finding":"CB2 receptors are most abundantly expressed in peripheral blood and tonsillar B cells among leukocytes; CB2 expression is downregulated during B-cell differentiation (lowest in germinal-center centroblasts); CD40-mediated activation upregulates CB2 within 24 h; CB2 agonist CP55,940 enhances CD40-mediated B-cell proliferation in a CB2-antagonist-reversible manner.","method":"Anti-CB2 immunopurified antibody staining, dual-color confocal microscopy, RT-PCR, Western blot, flow cytometry, proliferation assays with selective antagonist SR144528","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, functional pharmacological validation","pmids":["9808554"],"is_preprint":false},{"year":1999,"finding":"HU-308, a CB2-selective agonist (Ki = 22.7 nM at CB2, >10 µM at CB1), inhibits forskolin-stimulated cAMP production in CB2-transfected cells but not CB1-transfected cells, and produces anti-inflammatory and peripheral analgesic effects blocked by CB2 antagonist SR-144528 but not CB1 antagonist SR-141716A, confirming peripheral CB2-mediated signaling.","method":"Radioligand binding, cAMP assay in transfected cells, in vivo pharmacology with selective antagonists","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro receptor assays plus in vivo pharmacological validation with selective antagonists","pmids":["10588688"],"is_preprint":false},{"year":2002,"finding":"Rat CB2 (rCB2) was cloned and found to be 410 amino acids, with a longer C-terminus than human or mouse CB2; rCB2 activates MAP kinase (ERK1/2) when stably expressed in CHO cells, establishing MAPK activation as a CB2 signaling output.","method":"cDNA library cloning, CHO cell stable expression, MAPK phosphorylation assay","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, receptor cloning with functional MAPK readout","pmids":["12084572"],"is_preprint":false},{"year":2002,"finding":"CB2 cannabinoid receptor was functionally expressed in Pichia pastoris with retained pharmacological binding profile; purified receptor was confirmed by MALDI/TOF and ESI mass spectrometry, providing the first purified preparation for structural characterization.","method":"Heterologous expression in yeast, radioligand binding, metal-chelating chromatography purification, mass spectrometry peptide sequencing","journal":"Protein expression and purification","confidence":"Medium","confidence_rationale":"Tier 2 — functional reconstitution of purified receptor, single lab","pmids":["12460775"],"is_preprint":false},{"year":2003,"finding":"CB2 receptor activation with selective agonist JWH-133 induced growth inhibition of skin tumors in vivo accompanied by increased apoptosis and impaired tumor vascularization (decreased VEGF, placental growth factor, angiopoietin 2 expression) and abrogation of EGF-R function.","method":"In vivo tumor model (nude mice), immunohistochemistry, RT-PCR for angiogenic factors, pharmacological manipulation with selective CB2 agonist","journal":"Journal of Clinical Investigation","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic/pharmacological model with defined molecular readouts","pmids":["12511587"],"is_preprint":false},{"year":2003,"finding":"CB2 receptors on microglial cells mediate blockade of β-amyloid-induced microglial activation and neurotoxicity; cannabinoids including the selective CB2 agonist JWH-133 blocked Aβ-induced microglial activation (mitochondrial activity, TNF-α release, cell morphology) and abrogated microglia-mediated neurotoxicity in cortical co-cultures.","method":"Primary microglial cultures, rat cortical co-cultures, selective CB2 agonist, TNF-α ELISA, mitochondrial activity assay, intracerebroventricular WIN55,212-2 in rats","journal":"Journal of Neuroscience","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro and in vivo approaches, replicated with selective CB2 agonist","pmids":["15728830"],"is_preprint":false},{"year":2003,"finding":"Fatty acid amide hydrolase (FAAH) and CB2 receptors are selectively and abundantly expressed in neuritic plaque-associated astrocytes and microglia, respectively, in Alzheimer's disease brain, while CB1 expression remains unchanged, suggesting CB2 upregulation in neuroinflammation.","method":"Immunohistochemical analysis with specific polyclonal antibodies on postmortem AD and control brain sections","journal":"Journal of Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — direct protein localization by immunohistochemistry, well-controlled with specific antibodies","pmids":["14657172"],"is_preprint":false},{"year":2003,"finding":"CB2 receptor (but not CB1) mediates ACPA-induced microglial cell migration via Gi/o protein-coupled signaling; this effect is blocked by CB2 antagonists (SR144528, cannabinol) and abn-CBD receptor antagonists, but not by CB1 antagonist SR141716A.","method":"BV-2 microglial cell migration assay, pertussis toxin pretreatment, selective receptor antagonists","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection with selective antagonists in functional migration assay","pmids":["12921861"],"is_preprint":false},{"year":2005,"finding":"CB2 receptors are upregulated in hepatic myofibroblasts/activated stellate cells in cirrhotic liver (absent from normal liver); CB2 activation triggers antifibrogenic effects including growth inhibition (via cyclooxygenase-2) and apoptosis (via oxidative stress); CB2-/- mice develop enhanced liver fibrosis after CCl4 treatment.","method":"Immunohistochemistry on human liver biopsies, RT-PCR, GTPγS assays, culture assays with COX-2 inhibitors, ROS measurement, CB2 knockout mouse model","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including human tissue, cell culture, and knockout mouse, replicated across models","pmids":["15765409"],"is_preprint":false},{"year":2006,"finding":"CB2-deficient mice exhibit markedly accelerated age-related trabecular bone loss, increased osteoclast number, and decreased osteoblast precursors; a CB2-specific agonist inhibits proliferation of osteoclast precursors, reduces RANKL expression in bone marrow-derived osteoblasts/stromal cells, and attenuates ovariectomy-induced bone loss, demonstrating CB2 is essential for normal bone mass maintenance.","method":"CB2 knockout mice, histomorphometry, bone marrow colony assays, pharmacological treatment with CB2-selective agonist, ovariectomy model","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus pharmacological rescue, multiple cellular and in vivo readouts","pmids":["16407142"],"is_preprint":false},{"year":2006,"finding":"Alkylamides from Echinacea (dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide A1 and dodeca-2E,4E-dienoic acid isobutylamide A2) bind CB2 with Ki ~60 nM (>25-fold selective over CB1) and elevate total intracellular Ca2+ in CB2-positive HL60 cells via CB2, blocked by CB2 antagonist SR144528; they also upregulate constitutive IL-6 in a CB2-dependent manner.","method":"Radioligand displacement assay ([3H]CP-55,940), Ca2+ imaging in CB2+ vs CB2- cells, selective antagonist, IL-6 measurement","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — binding confirmed by displacement, functional Ca2+ and cytokine readout with genetic/pharmacological controls","pmids":["16547349"],"is_preprint":false},{"year":2007,"finding":"CB2 activation with the selective agonist JWH133 protects against hepatic ischemia/reperfusion injury by decreasing inflammatory cell infiltration, tissue TNF-α, MIP-1α, MIP-2, lipid peroxidation, and ICAM-1 expression; CB2-/- mice develop increased I/R-induced tissue damage, confirming CB2-mediated hepatoprotection.","method":"In vivo mouse I/R model, CB2-/- mice, JWH133 pharmacological treatment, cytokine ELISA, lipid peroxidation assay, ICAM-1/VCAM-1 expression, neutrophil adhesion assay","journal":"FASEB Journal","confidence":"High","confidence_rationale":"Tier 2 — pharmacological and genetic approaches in vivo with defined molecular endpoints","pmids":["17327359"],"is_preprint":false},{"year":2007,"finding":"CB2 receptor activation attenuates TNF-α-induced NF-κB and RhoA activation, upregulation of ICAM-1 and VCAM-1, MCP-1 expression, transendothelial monocyte migration, and monocyte-endothelial adhesion in human coronary artery endothelial cells, identifying CB2 as a regulator of endothelial inflammatory signaling.","method":"Human coronary artery endothelial cell cultures, Western blot, RT-PCR, NF-κB luciferase reporter, transendothelial migration assay, monocyte adhesion assay, in vivo aorta experiments","journal":"American Journal of Physiology. Heart and Circulatory Physiology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro and in vivo endpoints with CB2-selective pharmacology","pmids":["17660390"],"is_preprint":false},{"year":2007,"finding":"CB2 receptor inverse agonist Sch.414319 downregulates phosphorylation of the monocyte-specific actin-bundling protein L-plastin in human monocytes, suggesting a mechanism for CB2-mediated inhibition of immune cell motility.","method":"Biochemical profiling across 45 enzymes and 80 GPCRs/ion channels, protein phosphorylation analysis in human monocytes, in vivo immune cell mobility assay","journal":"British Journal of Pharmacology","confidence":"Medium","confidence_rationale":"Tier 2–3 — selective compound, phosphoproteomics, in vivo validation; single lab","pmids":["17906679"],"is_preprint":false},{"year":2008,"finding":"CB2 receptor activation (JWH133) mediates antinociception in wild-type mice, with significantly reduced effects in CB2-/- mice, while morphine antinociception was unaffected in CB2-/- mice, genetically confirming that AM1241 produces antinociception specifically through CB2 receptors.","method":"CB2 knockout mice, thermal nociception assay, pharmacological challenge with selective agonist AM1241 and WIN55,212-2","journal":"Pain","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with pharmacological validation, clean phenotypic readout","pmids":["16563625"],"is_preprint":false},{"year":2009,"finding":"CB2 receptor is expressed in mouse male germ cells; the selective CB2 agonist JWH133 induces ERK1/2 MAPK phosphorylation in spermatogonia and promotes their progression toward meiosis (increased SCP3-positive cells and meiotic prophase gene expression), with 2-AG acting as the autocrine endocannabinoid signal.","method":"Purified germ cell fractions, primary spermatogonia cultures, selective CB2 agonist treatment, ERK1/2 Western blot, BrdU incorporation, meiotic marker immunostaining","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with selective pharmacology and cell-specific readouts","pmids":["19541620"],"is_preprint":false},{"year":2009,"finding":"CB2 receptor gene (CNR2) has two promoters transcribing distinct isoforms: CB2A (testis/brain-predominant) and CB2B (spleen/peripheral-predominant); mouse CB2A expression in cerebellum is upregulated by the mixed CB receptor agonist WIN55212-2.","method":"Genomic mapping, RT-PCR with isoform-specific primers, Northern blot, drug treatment of mice","journal":"Genes, Brain, and Behavior","confidence":"Medium","confidence_rationale":"Tier 2 — genomic and transcript analysis across species with pharmacological manipulation","pmids":["19496827"],"is_preprint":false},{"year":2009,"finding":"GPR55 and CB2 receptors physically interact in human neutrophils; GPR55 activation augments CB2-mediated migration while inhibiting CB2-mediated degranulation and ROS production; mechanistically, GPR55 and CB2 interfere with each other's signaling at the level of small GTPases Rac2 and Cdc42.","method":"Human neutrophils and HL60 cells, co-immunoprecipitation, BRET, migration assays, degranulation assay, ROS production assay, dominant-negative small GTPase constructs","journal":"Cell Research","confidence":"High","confidence_rationale":"Tier 2 — co-IP plus BRET plus functional mechanistic dissection of GTPase signaling","pmids":["21467997"],"is_preprint":false},{"year":2009,"finding":"CB2 receptor mRNA and protein are expressed in rat brain (including ventral midbrain); mice with reduced CB2 function due to the R63 allele of rs2501432 show lower cAMP responses in transfected CHO cells; CB2 antagonist AM630 exacerbates MK-801- or methamphetamine-induced prepulse inhibition deficits in mice.","method":"RT-PCR, in situ hybridization, CHO cell functional assay (cAMP), human genetic association, pharmacological behavioral test","journal":"Biological Psychiatry","confidence":"Medium","confidence_rationale":"Tier 2–3 — functional cell assay for variant plus pharmacological behavioral readout; single lab","pmids":["19931854"],"is_preprint":false},{"year":2011,"finding":"CB2 receptor-selective agonist HU-308 activates the PI3K/Akt/mTORC1 pathway in hippocampal neural progenitor cells, inhibiting p27Kip1 and inducing proliferation; this effect is blocked by CB2 antagonist SR144528, PI3K/Akt/mTORC1 inhibitors, and absent in CB2-deficient mouse neural progenitors.","method":"HiB5 NP cell cultures, brain organotypic cultures, CB2-/- mice, Western blot for p-Akt/p-S6/p27, BrdU incorporation, pharmacological inhibitors, CB2-deficient NP cells","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches in vitro and in vivo with genetic and pharmacological controls","pmids":["22102284"],"is_preprint":false},{"year":2011,"finding":"CB2 receptors promote mouse neural stem/progenitor cell proliferation via phosphoinositide-3-kinase/Akt signaling; selective CB1 and CB2 antagonists block basal neurosphere proliferation suggesting endocannabinoid tone; PI3K inhibitor BML-257 blocks cannabinoid agonist-stimulated proliferation.","method":"Neurosphere culture, BrdU incorporation, selective CB1/CB2 agonists and antagonists, PI3K inhibitor","journal":"European Journal of Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection with functional readout; single lab","pmids":["17328768"],"is_preprint":false},{"year":2011,"finding":"CB2 receptor in osteoblasts activates a Gi protein–Erk1/2–MAPKAPK2–CREB–cyclin D1 mitogenic axis; CB2 agonist-induced osteoblast proliferation is blocked by pertussis toxin, MEK-Erk1/2 inhibitors (PD098059, U0126), and Mapkapk2 siRNA, identifying the signaling sequence for CB2-driven bone formation.","method":"MC3T3-E1 and primary calvarial osteoblast cultures, pertussis toxin, selective kinase inhibitors, siRNA knockdown, Western blot, CREB reporter, cyclin D1 RT-PCR","journal":"Journal of Bone and Mineral Research","confidence":"High","confidence_rationale":"Tier 2 — multiple inhibitors and siRNA defining a sequential signaling pathway, replicated in two cell models","pmids":["20803555"],"is_preprint":false},{"year":2011,"finding":"CB2 and CB1 receptors form functional heteromers in rat brain (pineal gland, nucleus accumbens, globus pallidus) and in transfected neuronal cells; co-activation of both receptors within CB1–CB2 heteromers produces negative cross-talk in Akt phosphorylation and neurite outgrowth; heteromers exhibit bidirectional cross-antagonism where CB1 antagonists block CB2 agonist effects and vice versa.","method":"BRET, FRET, co-immunoprecipitation in transfected neuronal cells and rat brain tissue, Akt phosphorylation assay, neurite outgrowth measurement","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — biophysical (BRET/FRET) plus biochemical (co-IP) plus functional (Akt, neurite) in both heterologous and native brain tissue","pmids":["22532560"],"is_preprint":false},{"year":2013,"finding":"CB2 receptor activation by trans-caryophyllene ameliorates ischemic neuronal injury through AMPK/CREB signaling: TC enhanced phosphorylation of AMPK and CREB and increased BDNF expression; AMPK and CREB inhibitors abolished neuroprotection; TC had no effect on Akt or ERK activity, distinguishing this pathway from canonical CB2 signaling.","method":"Rat cortical neuron/glia cultures, OGD/reoxygenation model, Western blot, selective inhibitors of AMPK and CREB, in vivo MCAo model with infarct measurement","journal":"American Journal of Pathology","confidence":"Medium","confidence_rationale":"Tier 2 — selective pharmacological pathway dissection in vitro and in vivo with AM630 reversal controls","pmids":["23414569"],"is_preprint":false},{"year":2013,"finding":"Agonist-induced formation of CB2–GPR55 heteromers in cancer cells produces unique signaling: ERK1/2-MAPK activation is potentiated while GPR55-mediated transcription factor activation (NFAT, NF-κB, CRE) is reduced; CB2 co-expression modifies GPR55 signaling and vice versa; modulation of these heteromers alters antitumoral activity of cannabinoids in vivo.","method":"Co-immunoprecipitation, BRET in HEK293 cells, label-free real-time assays (Epic DMR, CellKey impedance), ERK1/2-MAPK phosphorylation, gene reporter assays, in vivo tumor model","journal":"British Journal of Pharmacology","confidence":"High","confidence_rationale":"Tier 1–2 — BRET plus co-IP plus multiple functional signaling assays plus in vivo validation","pmids":["25048571"],"is_preprint":false},{"year":2014,"finding":"Agonist-induced CB2–GPR55 heteromers in cancer cells exhibit unique signaling properties distinct from either receptor alone; in vivo, modulation of CB2–GPR55 heteromers modifies antitumoral efficacy of cannabinoids.","method":"Co-immunoprecipitation, proximity ligation assay, ERK signaling assays, in vivo tumor model, shRNA modulation of CB2","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple biochemical approaches plus in vivo validation","pmids":["24942731"],"is_preprint":false},{"year":2014,"finding":"CB2 receptors localize to endolysosomes as well as the plasma membrane; intracellular CB2 activation by microinjected agonists (2-AG, anandamide, WIN55,212-2) triggers fast, transient Ca2+ elevation from inositol 1,4,5-trisphosphate-sensitive and acidic-like Ca2+ stores via Gq coupling, whereas extracellular anandamide is ineffective; plasmalemmal CB2 activation by 2-AG and WIN55,212-2 triggers delayed, Gq-mediated Ca2+ responses.","method":"Ca2+ imaging in CB2-expressing U2OS cells, intracellular microinjection, selective CB2 antagonist AM630, Gq inhibitors, endolysosomal markers","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1–2 — novel subcellular localization with functional consequence, intracellular vs extracellular agonist delivery, multiple controls","pmids":["25033246"],"is_preprint":false},{"year":2015,"finding":"HER2 upregulates CB2 expression via the transcription factor ELK1 through the ERK cascade; elevated CB2 activates HER2 pro-oncogenic signaling at the level of the tyrosine kinase c-SRC; HER2 and CB2 form heteromers in breast cancer cells; genetic inactivation of CB2 impairs tumor generation and progression in MMTV-neu mice.","method":"siRNA/shRNA knockdown, overexpression, co-immunoprecipitation, proximity ligation assay, colocalization, ELK1 reporter, MMTV-neu CB2-/- mouse model, human tumor tissue arrays","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal biochemical approaches plus genetic mouse model plus human tissue validation","pmids":["25855725"],"is_preprint":false},{"year":2015,"finding":"CB2 receptor mediates antinociception in a CB2-/- validated model; AM1241 antinociception is absent in CB2-/- mice but morphine antinociception is normal, confirming specificity; CB2 knockout mice exhibited robust ddC-induced neuropathy (replicated in antiretroviral model).","method":"CB2 knockout mice, thermal nociception and mechanical allodynia assays, selective CB2 agonists","journal":"Pain (replicated in 2022 paper PMID:35001054 and earlier PMID:16563625)","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout validated across multiple studies and models","pmids":["16563625","35001054"],"is_preprint":false},{"year":2016,"finding":"Functional CB2 receptors are expressed in VTA dopamine neurons in rats; CB2 agonist JWH133 inhibits VTA DA neuronal firing in single dissociated neurons; local CB2 agonist in nucleus accumbens inhibits cocaine-enhanced extracellular DA and intravenous cocaine self-administration, blocked by CB2 antagonist AM630.","method":"In situ hybridization, immunohistochemistry, single-cell electrophysiology, in vivo microdialysis, i.v. cocaine self-administration with intra-NAcc microinjection","journal":"Addiction Biology","confidence":"High","confidence_rationale":"Tier 2 — electrophysiology plus in vivo microdialysis plus behavioral pharmacology with site-specific and receptor-selective approaches","pmids":["26833913"],"is_preprint":false},{"year":2017,"finding":"B-lymphoid transcription factors PAX5 and IKZF1 transcriptionally repress CNR2 as part of a metabolic gatekeeper program; CNR2 is identified as a central effector restricting glucose and energy supply in B-lymphoid cells; pharmacological CNR2 agonism synergizes with glucocorticoids to induce energy crisis and cell death in pre-B ALL.","method":"ChIP-seq, RNA-seq, CRISPR/Cas9 screen of PAX5/IKZF1 transcriptional targets, metabolic analysis, pharmacological CB2 agonism in pre-B ALL mouse model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 — CRISPR screen plus ChIP-seq plus metabolic assays plus in vivo validation","pmids":["28792788"],"is_preprint":false},{"year":2018,"finding":"Agonist co-activation of CXCR4 and CB2 induces heterodimer formation on cancer cell membranes, decreasing Gα13 and RhoA protein levels, abrogating RhoA-mediated cytoskeletal rearrangement, reducing integrin α5 (ITGA5) expression, and inhibiting cell migration, invasion, and adhesion to extracellular matrices.","method":"Co-immunoprecipitation, Western blot, RhoA activation assay, migration/invasion/adhesion assays, siRNA knockdown in prostate cancer cells","journal":"Molecular Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2–3 — co-IP plus functional signaling and migration readouts; single lab","pmids":["29330286"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of human CB2 in complex with antagonist AM10257 at 2.8 Å resolution; the structure reveals a binding pose distinct from CB1 but extracellular conformation similar to agonist-bound CB1, explaining AM10257's unexpected opposing functional profile (CB2 antagonism vs CB1 agonism); mutagenesis and molecular docking identify molecular basis for CB1/CB2 functional selectivity and provide insight into CB2 activation mechanism.","method":"X-ray crystallography at 2.8 Å, site-directed mutagenesis, molecular docking, functional pharmacology","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis plus functional validation, published in Cell","pmids":["30639103"],"is_preprint":false},{"year":2019,"finding":"Cannabichromene (CBC) is a selective CB2 receptor agonist: it activates CB2 but not CB1 to produce cell hyperpolarization in AtT20 cells, an effect blocked by AM630 and sensitive to pertussis toxin (Gi coupling); CBC induces loss of cell-surface CB2 receptors and receptor desensitization, indicating recruitment of regulatory mechanisms.","method":"AtT20 cells stably expressing HA-tagged CB1 or CB2, membrane potential assay, receptor internalization assay, pertussis toxin treatment, selective antagonist AM630","journal":"British Journal of Pharmacology","confidence":"High","confidence_rationale":"Tier 1–2 — functional electrophysiology-based assay with Gi coupling demonstrated by pertussis toxin sensitivity, receptor internalization assay","pmids":["31368508"],"is_preprint":false},{"year":2019,"finding":"Cannabinoids suppress innate immunity to oral pathogens via a CB2/PI3K axis: THC, CBD, and CBN suppress P. gingivalis-induced cytokine production in human innate cells through CB2 and PI3K; CB2-/- mice lack this suppression in an oral infection model in vivo.","method":"Human monocyte cultures, siRNA gene silencing, pharmacological PI3K inhibition, CB2-/- mouse oral infection model, ELISA cytokine measurement","journal":"Frontiers in Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA, pharmacological, and genetic knockout validation of CB2/PI3K pathway","pmids":["31681262"],"is_preprint":false},{"year":2022,"finding":"CNR2 binds to JAK1 and inhibits downstream STAT signaling in T cells; THC and anandamide impair tumor-specific T cell function through CNR2; discovered using a FLAG-tagged Cnr2 knock-in mouse model and co-immunoprecipitation.","method":"FLAG-tagged Cnr2 knock-in mouse model, co-immunoprecipitation of CNR2 with JAK1, STAT phosphorylation assay, tumor-specific T cell functional assay, in vivo tumor models","journal":"Signal Transduction and Targeted Therapy","confidence":"High","confidence_rationale":"Tier 2 — endogenous tagged protein co-IP in knock-in mice plus functional signaling readout; novel binding partner identification","pmids":["35383142"],"is_preprint":false},{"year":2022,"finding":"CB2 localized specifically to peripheral sensory neurons (advillin+ cells) mediates both antinociceptive efficacy of CB2 agonists and sparing of morphine tolerance in a ddC-induced neuropathy model; advillinCre/+;CB2f/f conditional knockout mice lack CB2 agonist antinociception and morphine tolerance sparing, while retaining ddC-induced neuropathy and morphine antinociception.","method":"Conditional knockout mice (advillinCre/+;CB2f/f), mechanical allodynia and cold allodynia assays, morphine tolerance protocol, proinflammatory cytokine mRNA measurement","journal":"Pharmacological Research","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific conditional knockout with multiple behavioral and molecular readouts","pmids":["36417942"],"is_preprint":false},{"year":2022,"finding":"CB2 expressed in epidermal keratinocytes, Langerhans cells, dendritic cells in dermis, and Merkel cells mediates suppression of chemotherapy-induced peripheral neuropathic nociception; Langerhans cells are dynamically increased in epidermis after paclitaxel treatment; intraplantar CB2 agonist AM1710 elevates IL-10 mRNA in lumbar spinal cord.","method":"CB2-GFP BAC reporter mice, anti-GFP immunolabeling, co-expression with cell-type markers, intraplantar drug administration, mechanical/cold allodynia assays, spinal cord cytokine mRNA","journal":"Pain","confidence":"Medium","confidence_rationale":"Tier 2 — direct cell-type localization by reporter mouse plus pharmacological functional validation","pmids":["35001054"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of CB2 in complex with selective agonists (LEI-102, APD371, HU308, CP55,940) identify key residues for CB2 activation; highly lipophilic agonists (HU308, endocannabinoids) access the binding pocket via a membrane channel in TM1-TM7, while more polar agonists (LEI-102, APD371, CP55,940) do not, revealing that lipophilicity governs the route of CB2 engagement.","method":"Cryo-EM structural determination, binding kinetics, site-directed mutagenesis, molecular modeling, oral efficacy in chemotherapy-induced nephropathy model","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures with mutagenesis and functional validation, multiple ligands studied","pmids":["36922494"],"is_preprint":false},{"year":2024,"finding":"CB2 receptor forms homodimers; a homobivalent ligand simultaneously occupying the orthosteric site of one CB2 protomer and a membrane-oriented allosteric pocket (between TM1 and TM7) of the partner protomer locks the homodimer, increasing potency of Gi-mediated signaling and enhancing β-arrestin recruitment.","method":"Computational docking, pharmacological assays (cAMP/Gi signaling, β-arrestin recruitment), bivalent ligand design with 14-methylene linker","journal":"Pharmacological Research","confidence":"Medium","confidence_rationale":"Tier 2–3 — computational plus pharmacological functional assays; single lab, no structural validation of dimer","pmids":["39179054"],"is_preprint":false},{"year":2008,"finding":"CB2 receptor mRNA and protein are expressed in dopaminergic neurons of the VTA in mice; CB2 receptors are predominantly located on post-synaptic elements in rodent brain as determined by electron microscopy; CB2-Rs are modulated in brain following exposure to stressors and abused drugs.","method":"RT-PCR, immunoblotting, immunohistochemistry, transmission electron microscopy, in situ hybridization, hippocampal cultures, antisense oligonucleotide injection","journal":"PLoS ONE","confidence":"Medium","confidence_rationale":"Tier 2 — direct EM-based subcellular localization with functional behavioral follow-up","pmids":["18286196"],"is_preprint":false},{"year":2008,"finding":"CB2 receptor controls myeloid progenitor cell trafficking toward inflamed spinal cord in EAE; CB2-/- mice show exacerbated disease with increased myeloid progenitor recruitment, T-lymphocyte infiltration, and microglial activation; CB2 activation reduces EAE symptoms through modulation of CCL2, CCL3, CCL5 chemokines and CCR1, CCR2 receptors.","method":"CB2-/- mouse EAE model, bone marrow transfer, selective CB2 agonist pharmacology, flow cytometry, RT-PCR for chemokines/receptors, histological analysis","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus bone marrow transfer plus pharmacological activation with mechanistic chemokine pathway dissection","pmids":["18334483"],"is_preprint":false},{"year":2009,"finding":"CB2 receptor activation inhibits macrophage ROS production via Rap1 activation; CB1 promotes pro-inflammatory ROS and p38-MAPK phosphorylation in macrophages, while CB2 activates Rap1 to negatively regulate CB1-stimulated ROS, TNF-α, and MCP-1 production; dominant-negative Rap1 enhanced CB1-dependent ROS.","method":"Selective expression of CB1 or CB2 in peritoneal macrophages, flow cytometry for ROS, p38-MAPK Western blot, pull-down assay for Rap1 activation, dominant-negative Rap1 construct","journal":"Cardiovascular Research","confidence":"High","confidence_rationale":"Tier 2 — selective receptor expression plus pull-down assay for Rap1 plus dominant-negative construct, clean mechanistic dissection","pmids":["19596672"],"is_preprint":false},{"year":2012,"finding":"CB2 receptor protects against balloon-induced neointima formation; CB2 activation (JWH133) reduces intimal nuclei, smooth muscle cells, macrophages, and proliferating cells; CB2-/- mice develop increased intima formation with elevated macrophage adhesion, migration, and smooth muscle cell proliferation, and elevated CCR1, CCR5, and CCL2 mRNA in CB2-/- macrophages.","method":"CB2-/- mice, pharmacological CB2 activation, carotid balloon injury model, bone marrow-derived macrophage adhesion/migration assays, smooth muscle cell proliferation assay, RT-PCR for adhesion molecules and chemokines","journal":"American Journal of Physiology. Heart and Circulatory Physiology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus pharmacological activation plus in vitro cellular mechanism","pmids":["22227125"],"is_preprint":false},{"year":2013,"finding":"CB2 receptor modulates axon guidance in the retino-thalamic pathway; CB2R-induced growth cone morphological changes are PKA-dependent and require the netrin-1 receptor DCC (Deleted in Colorectal Cancer); cnr2-/- mice exhibit abnormal eye-specific segregation of retinal projections in the dorsal lateral geniculate nucleus.","method":"In vitro retinal axon assays, in vivo cnr2-/- mouse model, pharmacological CB2 manipulation, PKA inhibitor, immunofluorescence for DCC","journal":"PLoS ONE","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout phenotype plus in vitro mechanistic dissection (PKA dependence, DCC requirement)","pmids":["23951024"],"is_preprint":false},{"year":2021,"finding":"CB2 receptor expression is increased in hippocampal neurons bearing accumulated TAU in a TAU-dependent manner; CB2 ablation in mice protects from neurodegeneration induced by hTAUP301L overexpression, as shown by preserved cognitive behavior, synaptic plasticity, and reduced insoluble TAU aggregates; CB2 upregulation is confirmed in postmortem Alzheimer's disease brain samples.","method":"AAV-TAU mouse models, CB2-/- genetic knockout, gene expression analysis, immunofluorescence, behavioral tests, synaptic plasticity measurement, Western blot for TAU aggregates, human AD postmortem brain","journal":"Acta Neuropathologica Communications","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout with behavioral and molecular phenotypes, validated in human tissue; single lab","pmids":["34001284"],"is_preprint":false},{"year":2017,"finding":"CB2 receptor stimulation (JWH133) inhibits NLRP3 inflammasome activation in inflamed skin macrophages; CB2 knockout mice show attenuated EA effects on NLRP3 inflammasomes; in vitro CB2 stimulation in macrophage cell lines directly inhibits NLRP3 inflammasome activation, defining CB2 as a negative regulator of NLRP3 inflammasome.","method":"CFA-induced inflammatory pain rat model, electroacupuncture, CB2-/- mice, caspase-1 activity assay, Western blot, immunofluorescence, in vitro macrophage CB2 stimulation","journal":"Brain, Behavior, and Immunity","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout validation plus in vitro mechanism; single lab","pmids":["28782714"],"is_preprint":false}],"current_model":"CNR2 (CB2) is a Gi-protein-coupled receptor canonically expressed in immune tissues and peripheral organs (and more recently confirmed in brain neurons and glia) that, upon activation by endocannabinoids or synthetic agonists, inhibits adenylyl cyclase, activates ERK1/2-MAPK and PI3K/Akt/mTORC1 pathways, recruits β-arrestin, activates Rap1 to suppress ROS, inhibits NLRP3 inflammasome activation, and (from endolysosomal localization) couples to Gq to release Ca2+; CB2 forms heteromers with CB1, GPR55, CXCR4, and HER2 that create distinct signaling platforms, and its structural basis for ligand binding and activation has been established by crystal structure and cryo-EM studies revealing both orthosteric and membrane-channel access routes for agonists."},"narrative":{"teleology":[{"year":1993,"claim":"Cloning of CNR2 from spleen macrophages established the existence of a second cannabinoid receptor expressed in the periphery and molecularly distinct from the CNS-expressed CB1, resolving whether a single receptor mediated all cannabinoid effects.","evidence":"Molecular cloning from macrophage cDNA, radioligand binding in heterologous cells","pmids":["7689702"],"confidence":"High","gaps":["Post-translational modifications uncharacterized","No structural information","CNS expression not assessed beyond Northern blot"]},{"year":1996,"claim":"Demonstration that CB2 inhibits forskolin-stimulated cAMP production via Gi coupling in transfected cells identified the primary effector mechanism and confirmed functional conservation across species.","evidence":"cAMP assays in CHO cells stably expressing human or mouse CB2","pmids":["8679694"],"confidence":"High","gaps":["Downstream signaling beyond adenylyl cyclase unknown","No information on G-protein subtype specificity","No endogenous cell system tested"]},{"year":1998,"claim":"Mapping of CB2 expression to B-cell subsets and demonstration that CB2 agonism enhances CD40-driven B-cell proliferation provided the first functional link between CB2 signaling and adaptive immune cell biology.","evidence":"Confocal microscopy, flow cytometry, proliferation assays with CB2 antagonist reversal in tonsillar B cells","pmids":["9808554"],"confidence":"High","gaps":["Signaling intermediates between CB2 and proliferative machinery undefined","No in vivo B-cell functional data"]},{"year":2002,"claim":"Cloning of rat CB2 and demonstration that it activates ERK1/2-MAPK expanded the known CB2 effector repertoire beyond adenylyl cyclase inhibition, suggesting mitogenic signaling capacity.","evidence":"Stable CHO cell expression, MAPK phosphorylation assay","pmids":["12084572"],"confidence":"Medium","gaps":["Pathway intermediates between Gi and ERK not mapped","Relevance to endogenous immune cells not tested"]},{"year":2003,"claim":"CB2 was shown to mediate microglial migration, suppress Aβ-induced microglial neurotoxicity, and become upregulated on microglia in Alzheimer's disease brain, overturning the view that CB2 is absent from the CNS and identifying it as a neuroinflammatory regulator.","evidence":"Primary microglia migration assays, cortical co-cultures with selective CB2 agonist JWH-133, immunohistochemistry on postmortem AD brain","pmids":["15728830","14657172","12921861"],"confidence":"High","gaps":["Whether microglial CB2 is neuroprotective or disease-promoting in vivo remained unclear","Mechanism of CB2 transcriptional upregulation in neuroinflammation unknown"]},{"year":2005,"claim":"CB2-knockout mice developed exacerbated hepatic fibrosis after toxic injury, and CB2 activation triggered apoptosis of hepatic myofibroblasts, establishing CB2 as a physiological antifibrogenic brake in liver.","evidence":"CB2−/− mice with CCl4 fibrosis model, immunohistochemistry on human cirrhotic liver, ROS and COX-2 assays","pmids":["15765409"],"confidence":"High","gaps":["Downstream transcriptional program of CB2 in stellate cells not defined","Whether CB2 agonists can reverse established fibrosis not tested"]},{"year":2006,"claim":"Demonstration that CB2-knockout mice exhibit accelerated age-related bone loss and that CB2 agonism inhibits osteoclast precursor proliferation and RANKL expression revealed CB2 as essential for bone mass homeostasis.","evidence":"CB2−/− mice, histomorphometry, ovariectomy rescue with CB2 agonist, bone marrow colony assays","pmids":["16407142"],"confidence":"High","gaps":["Signaling intermediates in osteoclast precursors not mapped","Human genetic association with osteoporosis not established"]},{"year":2007,"claim":"CB2 activation suppressed TNF-α-induced NF-κB, ICAM-1/VCAM-1, and monocyte transendothelial migration in coronary endothelial cells, and protected against hepatic ischemia/reperfusion injury in vivo, mechanistically linking CB2 to vascular inflammatory control.","evidence":"Human coronary artery endothelial cells, NF-κB reporter, CB2−/− I/R model, cytokine ELISAs","pmids":["17660390","17327359"],"confidence":"High","gaps":["Direct CB2 signaling events linking Gi to NF-κB suppression not fully resolved","Receptor desensitization kinetics in endothelium unknown"]},{"year":2008,"claim":"Detection of CB2 mRNA and protein on VTA dopamine neurons by electron microscopy, and demonstration that CB2 deficiency worsens autoimmune encephalomyelitis via enhanced myeloid progenitor trafficking, established CB2 function in both the CNS and in autoimmune cell migration control.","evidence":"Transmission EM in rodent brain, CB2−/− EAE model, bone marrow transfer, chemokine profiling","pmids":["18286196","18334483"],"confidence":"High","gaps":["Electrophysiological consequence of neuronal CB2 not yet shown at single-cell level","Mechanism of CB2-dependent chemokine regulation not mapped"]},{"year":2009,"claim":"CB2 was found to activate Rap1 in macrophages to suppress CB1-stimulated ROS and proinflammatory mediators, providing a molecular mechanism for CB2's anti-inflammatory role via small GTPase cross-talk; separately, GPR55–CB2 physical interaction was demonstrated to modulate neutrophil migration and degranulation through Rac2/Cdc42.","evidence":"Rap1 pull-down with dominant-negative constructs in macrophages; BRET and co-IP for GPR55–CB2 in neutrophils/HL60 cells","pmids":["19596672","21467997"],"confidence":"High","gaps":["Whether Rap1 axis operates in non-macrophage contexts unknown","GPR55–CB2 heteromer stoichiometry and structural basis undefined"]},{"year":2011,"claim":"CB2 was shown to activate PI3K/Akt/mTORC1 to promote neural progenitor proliferation and Gi–ERK1/2–MAPKAPK2–CREB–cyclin D1 for osteoblast mitogenesis, mapping cell-type-specific signaling cascades downstream of CB2; CB1–CB2 heteromers were identified in brain with bidirectional cross-antagonism on Akt and neurite outgrowth.","evidence":"CB2−/− neural progenitors, PI3K/Akt inhibitors, siRNA of MAPKAPK2, BRET/FRET/co-IP in neuronal cells and rat brain","pmids":["22102284","20803555","22532560"],"confidence":"High","gaps":["Heteromer stoichiometry not determined","In vivo consequence of CB1–CB2 heteromerization on behavior unknown","Whether mTORC1 axis contributes to tumor biology not tested"]},{"year":2014,"claim":"Discovery that CB2 localizes to endolysosomes and, upon intracellular agonist delivery, couples to Gq to release Ca²⁺ from IP3-sensitive and acidic stores demonstrated a previously unrecognized compartment-dependent signaling mode distinct from canonical plasma membrane Gi signaling.","evidence":"Microinjection of agonists into CB2-expressing U2OS cells, Ca²⁺ imaging, Gq inhibitors, endolysosomal markers","pmids":["25033246"],"confidence":"High","gaps":["Physiological ligand delivery route to endolysosomal CB2 unclear","Whether endolysosomal CB2 signaling occurs in immune cells not tested","Structural basis for Gq coupling not resolved"]},{"year":2015,"claim":"HER2 was found to transcriptionally upregulate CB2 via ELK1–ERK and to form HER2–CB2 heteromers that activate c-SRC pro-oncogenic signaling; CB2 genetic inactivation impaired HER2-driven mammary tumorigenesis, revealing CB2 as a co-opted oncogenic effector in breast cancer.","evidence":"siRNA/shRNA, co-IP, PLA, ELK1 reporter, MMTV-neu CB2−/− mouse model, human tumor tissue arrays","pmids":["25855725"],"confidence":"High","gaps":["Whether HER2–CB2 heteromer is druggable unknown","Downstream transcriptional program of CB2–c-SRC not mapped"]},{"year":2016,"claim":"Electrophysiological recording from single dissociated VTA DA neurons confirmed functional CB2 receptors inhibit neuronal firing, and intra-accumbal CB2 agonism reduced cocaine-enhanced dopamine and self-administration, establishing a direct neuronal function for CB2 in reward circuitry.","evidence":"Single-cell electrophysiology, in vivo microdialysis, intra-NAcc microinjection with CB2 antagonist reversal","pmids":["26833913"],"confidence":"High","gaps":["Postsynaptic vs presynaptic CB2 mechanism in DA neurons not resolved","Whether CB2 modulates other addictive substances through same circuit not tested"]},{"year":2017,"claim":"CB2 was identified as a central effector of the PAX5/IKZF1 metabolic gatekeeper program in B-lymphoid cells, where it restricts glucose and energy supply; pharmacological CB2 agonism synergized with glucocorticoids to induce metabolic crisis in pre-B ALL, redefining CB2 as a metabolic checkpoint.","evidence":"CRISPR/Cas9 screen, ChIP-seq, RNA-seq, metabolic flux analysis, pre-B ALL mouse model","pmids":["28792788"],"confidence":"High","gaps":["Metabolic effectors downstream of CB2 (glucose transporter regulation) not fully mapped","Whether this mechanism operates outside B-lymphoid lineage unknown"]},{"year":2019,"claim":"The 2.8 Å crystal structure of CB2 bound to antagonist AM10257 revealed a ligand-binding pose distinct from CB1 and explained divergent functional selectivity between the two receptors, providing the first atomic-resolution template for CB2 drug design.","evidence":"X-ray crystallography, site-directed mutagenesis, molecular docking, functional pharmacology","pmids":["30639103"],"confidence":"High","gaps":["Active-state structure not yet available at this point","Mechanism of agonist-induced conformational change not resolved"]},{"year":2022,"claim":"CNR2 was found to physically bind JAK1 and suppress JAK-STAT signaling in T cells, with THC and anandamide impairing tumor-specific T cell responses through this axis, uncovering a non-canonical CB2 signaling mechanism relevant to tumor immune evasion.","evidence":"FLAG-Cnr2 knock-in mouse, endogenous co-IP of CNR2–JAK1, STAT phosphorylation, tumor-specific T cell functional assays","pmids":["35383142"],"confidence":"High","gaps":["Structural basis of CNR2–JAK1 interaction unknown","Whether JAK1 inhibition is Gi-dependent or independent not resolved","Relevance to non-tumor immunity untested"]},{"year":2022,"claim":"Conditional deletion of CB2 from peripheral sensory neurons (advillin+ cells) abolished CB2 agonist antinociception and morphine tolerance sparing, pinpointing the cell type and anatomical site responsible for CB2-mediated pain modulation.","evidence":"advillinCre/+;CB2f/f conditional knockout, mechanical and cold allodynia, morphine tolerance protocol","pmids":["36417942"],"confidence":"High","gaps":["Signaling pathway in sensory neurons mediating antinociception not defined","Whether central CB2 also contributes to pain behavior not addressed"]},{"year":2023,"claim":"Cryo-EM structures of CB2 with four selective agonists revealed that lipophilic agonists access the binding pocket through a membrane channel between TM1 and TM7, while polar agonists enter from the extracellular face, explaining ligand-dependent pharmacological differences and enabling rational design of pathway-selective agonists.","evidence":"Cryo-EM structural determination, binding kinetics, site-directed mutagenesis, molecular modeling","pmids":["36922494"],"confidence":"High","gaps":["Structures of CB2 heteromers not available","Whether membrane-channel entry route is physiologically utilized by endocannabinoids requires validation","No structure of CB2 in complex with Gq"]},{"year":null,"claim":"Key unresolved questions include the structural basis of CB2 heteromers (CB1, GPR55, HER2, CXCR4), the mechanism by which endolysosomal CB2 switches from Gi to Gq coupling, the full signaling cascade linking CB2 to JAK1 inhibition, and whether CB2's metabolic gatekeeper role in B-lymphoid cells extends to other immune lineages.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No heteromer structures available","Endolysosomal Gq coupling mechanism unresolved","CNR2–JAK1 structural interface undefined","Metabolic checkpoint function outside B-lineage untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,3,37]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[39,50]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,30,37]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[30]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,6,23,25,26,30,46]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,9,15,16,45,50]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[33,44]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[13,48]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[34]}],"complexes":["CB1-CB2 heteromer","CB2-GPR55 heteromer","CB2-HER2 heteromer","CB2-CXCR4 heteromer"],"partners":["CNR1","GPR55","ERBB2","CXCR4","JAK1","RAP1A","DCC"],"other_free_text":[]},"mechanistic_narrative":"CNR2 (CB2) is a Gi/o-protein-coupled cannabinoid receptor predominantly expressed in immune cells (B cells, macrophages, microglia) and peripheral tissues—with regulated expression also in CNS neurons—that transduces endocannabinoid and phytocannabinoid signals into anti-inflammatory, immunomodulatory, and metabolic outcomes [PMID:7689702, PMID:7556170, PMID:26833913]. Upon agonist binding, CB2 inhibits adenylyl cyclase, activates ERK1/2-MAPK, PI3K/Akt/mTORC1, AMPK/CREB, and Rap1 pathways, recruits β-arrestin, and—from endolysosomal compartments—couples to Gq to mobilize intracellular Ca²⁺, while negatively regulating NF-κB, RhoA, NLRP3 inflammasome, and JAK1-STAT signaling [PMID:8679694, PMID:22102284, PMID:25033246, PMID:19596672, PMID:28782714, PMID:35383142]. CB2 forms functionally distinct heteromers with CB1, GPR55, CXCR4, and HER2 that remodel downstream signaling selectivity, and its structural basis—including orthosteric and lipophilicity-gated membrane-channel agonist entry routes—has been defined by crystal and cryo-EM structures [PMID:22532560, PMID:25048571, PMID:30639103, PMID:36922494]. Genetic loss of CB2 in mice results in accelerated bone loss, exacerbated hepatic fibrosis, enhanced neuroinflammation, and altered pain sensitivity, establishing CB2 as a physiological brake on inflammation, bone resorption, and nociceptive signaling [PMID:16407142, PMID:15765409, PMID:18334483, PMID:36417942]."},"prefetch_data":{"uniprot":{"accession":"P34972","full_name":"Cannabinoid receptor 2","aliases":["CX5"],"length_aa":360,"mass_kda":39.7,"function":"Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis","subcellular_location":"Cell membrane; Cell projection, dendrite; Perikaryon","url":"https://www.uniprot.org/uniprotkb/P34972/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CNR2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CNR2","total_profiled":1310},"omim":[{"mim_id":"613599","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 12, LYSOPHOSPHOLIPASE; ABHD12","url":"https://www.omim.org/entry/613599"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"606928","title":"BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 3; BMND3","url":"https://www.omim.org/entry/606928"},{"mim_id":"606312","title":"PROTOCADHERIN-ALPHA 6; PCDHA6","url":"https://www.omim.org/entry/606312"},{"mim_id":"605051","title":"CANNABINOID RECEPTOR 2; CNR2","url":"https://www.omim.org/entry/605051"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":3.1},{"tissue":"lymphoid tissue","ntpm":8.4}],"url":"https://www.proteinatlas.org/search/CNR2"},"hgnc":{"alias_symbol":["CB2"],"prev_symbol":[]},"alphafold":{"accession":"P34972","domains":[{"cath_id":"1.20.1070.10","chopping":"21-169_178-223_234-315","consensus_level":"medium","plddt":92.7884,"start":21,"end":315}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P34972","model_url":"https://alphafold.ebi.ac.uk/files/AF-P34972-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P34972-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CNR2","jax_strain_url":"https://www.jax.org/strain/search?query=CNR2"},"sequence":{"accession":"P34972","fasta_url":"https://rest.uniprot.org/uniprotkb/P34972.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P34972/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P34972"}},"corpus_meta":[{"pmid":"9336020","id":"PMC_9336020","title":"Pharmacology of cannabinoid CB1 and CB2 receptors.","date":"1997","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/9336020","citation_count":1197,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20590558","id":"PMC_20590558","title":"CB2: a cannabinoid receptor with an identity crisis.","date":"2010","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20590558","citation_count":497,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10588688","id":"PMC_10588688","title":"HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10588688","citation_count":454,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27402121","id":"PMC_27402121","title":"The CB2 receptor and its role as a regulator of inflammation.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27402121","citation_count":439,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17105950","id":"PMC_17105950","title":"Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.","date":"2006","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17105950","citation_count":424,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16407142","id":"PMC_16407142","title":"Peripheral cannabinoid receptor, CB2, regulates bone mass.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16407142","citation_count":424,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11514083","id":"PMC_11514083","title":"CB2 cannabinoid receptor-mediated peripheral antinociception.","date":"2001","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/11514083","citation_count":334,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19152719","id":"PMC_19152719","title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.","date":"2009","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19152719","citation_count":324,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17141334","id":"PMC_17141334","title":"Cannabinoid CB2 receptor: a new target for controlling neural cell survival?","date":"2006","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17141334","citation_count":304,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30639103","id":"PMC_30639103","title":"Crystal Structure of the Human Cannabinoid Receptor CB2.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/30639103","citation_count":300,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28826534","id":"PMC_28826534","title":"CB1 and CB2 Receptor Pharmacology.","date":"2017","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/28826534","citation_count":254,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18615177","id":"PMC_18615177","title":"The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.","date":"2007","source":"Current neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18615177","citation_count":254,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22532560","id":"PMC_22532560","title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22532560","citation_count":192,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28861504","id":"PMC_28861504","title":"Cannabinoid CB1 and CB2 Receptor Signaling and Bias.","date":"2017","source":"Cannabis and cannabinoid research","url":"https://pubmed.ncbi.nlm.nih.gov/28861504","citation_count":169,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16356641","id":"PMC_16356641","title":"Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study.","date":"2005","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16356641","citation_count":164,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19150370","id":"PMC_19150370","title":"Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.","date":"2008","source":"Brain research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19150370","citation_count":162,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30611802","id":"PMC_30611802","title":"Progress in brain cannabinoid CB2 receptor research: From genes to behavior.","date":"2019","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30611802","citation_count":161,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21430651","id":"PMC_21430651","title":"Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.","date":"2011","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21430651","citation_count":154,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12084572","id":"PMC_12084572","title":"Cloning and molecular characterization of the rat CB2 cannabinoid receptor.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12084572","citation_count":149,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21626285","id":"PMC_21626285","title":"Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.","date":"2011","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/21626285","citation_count":147,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19931854","id":"PMC_19931854","title":"Brain cannabinoid CB2 receptor in schizophrenia.","date":"2009","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19931854","citation_count":143,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9808554","id":"PMC_9808554","title":"Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9808554","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21447538","id":"PMC_21447538","title":"CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity.","date":"2011","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21447538","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22102284","id":"PMC_22102284","title":"CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22102284","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23414569","id":"PMC_23414569","title":"Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23414569","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16395612","id":"PMC_16395612","title":"Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes.","date":"2006","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16395612","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26833913","id":"PMC_26833913","title":"Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats.","date":"2016","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/26833913","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26515747","id":"PMC_26515747","title":"Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26515747","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17328768","id":"PMC_17328768","title":"CB2 cannabinoid receptors promote mouse neural stem cell proliferation.","date":"2007","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17328768","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10750830","id":"PMC_10750830","title":"Expression of CB2 cannabinoid receptor mRNA in adult rat retina.","date":"2000","source":"Visual neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10750830","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19541620","id":"PMC_19541620","title":"The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19541620","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23865723","id":"PMC_23865723","title":"Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.","date":"2013","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23865723","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25048571","id":"PMC_25048571","title":"Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.","date":"2014","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25048571","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19333940","id":"PMC_19333940","title":"The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis.","date":"2009","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/19333940","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17189959","id":"PMC_17189959","title":"Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans.","date":"2006","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/17189959","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24942731","id":"PMC_24942731","title":"Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24942731","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25855725","id":"PMC_25855725","title":"Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.","date":"2015","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/25855725","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17906679","id":"PMC_17906679","title":"Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17906679","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18291574","id":"PMC_18291574","title":"Role of CB2 receptors in neuroprotective effects of cannabinoids.","date":"2008","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18291574","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14517981","id":"PMC_14517981","title":"3D structural model of the G-protein-coupled cannabinoid CB2 receptor.","date":"2003","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/14517981","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25704169","id":"PMC_25704169","title":"Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells.","date":"2015","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25704169","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28782714","id":"PMC_28782714","title":"Electroacupuncture inhibits NLRP3 inflammasome activation through CB2 receptors in inflammatory pain.","date":"2017","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28782714","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24877594","id":"PMC_24877594","title":"What we know and do not know about the cannabinoid receptor 2 (CB2).","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24877594","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12921861","id":"PMC_12921861","title":"Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors.","date":"2003","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12921861","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15556131","id":"PMC_15556131","title":"Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.","date":"2004","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15556131","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16451064","id":"PMC_16451064","title":"Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis.","date":"2006","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16451064","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31368508","id":"PMC_31368508","title":"Cannabichromene is a cannabinoid CB2 receptor agonist.","date":"2019","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31368508","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16026310","id":"PMC_16026310","title":"CB2 receptor ligands.","date":"2005","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16026310","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20133454","id":"PMC_20133454","title":"The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20133454","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12505700","id":"PMC_12505700","title":"Inhibition of pain responses by activation of CB(2) cannabinoid receptors.","date":"2002","source":"Chemistry and physics of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/12505700","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20166925","id":"PMC_20166925","title":"Cannabinoid CB(2) receptors in health and disease.","date":"2010","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20166925","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23855434","id":"PMC_23855434","title":"Role of cannabinoid CB2 receptor in the reinforcing actions of ethanol.","date":"2013","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/23855434","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39179054","id":"PMC_39179054","title":"Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/39179054","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20803555","id":"PMC_20803555","title":"CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts.","date":"2011","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/20803555","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17311616","id":"PMC_17311616","title":"Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease.","date":"2007","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/17311616","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10903395","id":"PMC_10903395","title":"The search for selective ligands for the CB2 receptor.","date":"2000","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/10903395","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35383142","id":"PMC_35383142","title":"Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2.","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35383142","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27215781","id":"PMC_27215781","title":"Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.","date":"2016","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/27215781","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31681262","id":"PMC_31681262","title":"Marijuana-Derived Cannabinoids Trigger a CB2/PI3K Axis of Suppression of the Innate Response to Oral Pathogens.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31681262","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24836296","id":"PMC_24836296","title":"Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.","date":"2014","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24836296","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16981823","id":"PMC_16981823","title":"Targeting the CB2 receptor for immune modulation.","date":"2006","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/16981823","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22197668","id":"PMC_22197668","title":"CB₂: therapeutic target-in-waiting.","date":"2011","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22197668","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26186541","id":"PMC_26186541","title":"Time-Dependent Protection of CB2 Receptor Agonist in Stroke.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26186541","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19480992","id":"PMC_19480992","title":"Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans.","date":"2009","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/19480992","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23951024","id":"PMC_23951024","title":"Cannabinoid receptor CB2 modulates axon guidance.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23951024","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35055161","id":"PMC_35055161","title":"New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35055161","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26406232","id":"PMC_26406232","title":"Expression Analysis of CB2-GFP BAC Transgenic Mice.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26406232","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36922494","id":"PMC_36922494","title":"Structural basis of selective cannabinoid CB2 receptor activation.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36922494","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25033246","id":"PMC_25033246","title":"Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors.","date":"2014","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25033246","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18468662","id":"PMC_18468662","title":"Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder.","date":"2008","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/18468662","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35906103","id":"PMC_35906103","title":"Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future.","date":"2022","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35906103","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20549374","id":"PMC_20549374","title":"Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.","date":"2010","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20549374","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35273503","id":"PMC_35273503","title":"Expression and Functions of the CB2 Receptor in Human Leukocytes.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35273503","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30055149","id":"PMC_30055149","title":"Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30055149","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29330286","id":"PMC_29330286","title":"Agonist-induced CXCR4 and CB2 Heterodimerization Inhibits Gα13/RhoA-mediated Migration.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/29330286","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37164044","id":"PMC_37164044","title":"CB2 receptor in the CNS: From immune and neuronal modulation to behavior.","date":"2023","source":"Neuroscience and biobehavioral reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37164044","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31215752","id":"PMC_31215752","title":"Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents.","date":"2019","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/31215752","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39064959","id":"PMC_39064959","title":"The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update.","date":"2024","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/39064959","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17727390","id":"PMC_17727390","title":"The cannabinoid CB(2) receptor: a good friend in the gut.","date":"2007","source":"Neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/17727390","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28752643","id":"PMC_28752643","title":"Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28752643","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19565271","id":"PMC_19565271","title":"The cannabinoid receptor type 2 (CNR2) gene is associated with hand bone strength phenotypes in an ethnically homogeneous family sample.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19565271","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35453624","id":"PMC_35453624","title":"Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Celiac Disease.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35453624","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31452735","id":"PMC_31452735","title":"HTR1D, TIMP1, SERPINE1, MMP3 and CNR2 affect the survival of patients with colon adenocarcinoma.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31452735","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27842450","id":"PMC_27842450","title":"The central cannabinoid receptor type-2 (CB2) and chronic pain.","date":"2016","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27842450","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12460775","id":"PMC_12460775","title":"Expression of CB2 cannabinoid receptor in Pichia pastoris.","date":"2002","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/12460775","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31517528","id":"PMC_31517528","title":"Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.","date":"2019","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31517528","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34001284","id":"PMC_34001284","title":"Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.","date":"2021","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/34001284","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35001054","id":"PMC_35001054","title":"A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.","date":"2022","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/35001054","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16621595","id":"PMC_16621595","title":"Bacterial expression of functional, biotinylated peripheral cannabinoid receptor CB2.","date":"2006","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/16621595","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20854251","id":"PMC_20854251","title":"Human platelets express authentic CB₁ and CB₂ receptors.","date":"2010","source":"Current neurovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/20854251","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27919827","id":"PMC_27919827","title":"PKCβII-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity.","date":"2016","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/27919827","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21945715","id":"PMC_21945715","title":"Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.","date":"2011","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21945715","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36551756","id":"PMC_36551756","title":"Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36551756","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27063942","id":"PMC_27063942","title":"Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.","date":"2016","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/27063942","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26370914","id":"PMC_26370914","title":"Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors.","date":"2015","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/26370914","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30063884","id":"PMC_30063884","title":"Pharmacological regulation of cannabinoid CB2 receptor modulates the reinforcing and motivational actions of ethanol.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30063884","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15277313","id":"PMC_15277313","title":"Cannabinoids and intestinal motility: welcome to CB2 receptors.","date":"2004","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15277313","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22227125","id":"PMC_22227125","title":"Cannabinoid receptor CB2 protects against balloon-induced neointima formation.","date":"2012","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22227125","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36417942","id":"PMC_36417942","title":"Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/36417942","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31725603","id":"PMC_31725603","title":"The association of endocannabinoid receptor genes (CNR1 and CNR2) polymorphisms with depression: A meta-analysis.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31725603","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7689702","id":"PMC_7689702","title":"Molecular characterization of a peripheral receptor for cannabinoids.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7689702","citation_count":3942,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7556170","id":"PMC_7556170","title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.","date":"1995","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7556170","citation_count":1352,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15728830","id":"PMC_15728830","title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.","date":"2005","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15728830","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14657172","id":"PMC_14657172","title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains.","date":"2003","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/14657172","citation_count":470,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15765409","id":"PMC_15765409","title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver.","date":"2005","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15765409","citation_count":390,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12511587","id":"PMC_12511587","title":"Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12511587","citation_count":311,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15266552","id":"PMC_15266552","title":"Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study.","date":"2004","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15266552","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15927811","id":"PMC_15927811","title":"Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin.","date":"2005","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/15927811","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17660390","id":"PMC_17660390","title":"CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.","date":"2007","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17660390","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19496827","id":"PMC_19496827","title":"Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.","date":"2009","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/19496827","citation_count":208,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17327359","id":"PMC_17327359","title":"Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury.","date":"2007","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17327359","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19596672","id":"PMC_19596672","title":"CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages.","date":"2009","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19596672","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18286196","id":"PMC_18286196","title":"Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18286196","citation_count":204,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28192788","id":"PMC_28192788","title":"Metabolic gatekeeper function of B-lymphoid transcription factors.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28192788","citation_count":197,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16547349","id":"PMC_16547349","title":"Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16547349","citation_count":186,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23471521","id":"PMC_23471521","title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.","date":"2013","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23471521","citation_count":184,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25863279","id":"PMC_25863279","title":"Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.","date":"2015","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/25863279","citation_count":161,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18092149","id":"PMC_18092149","title":"Presence of functional cannabinoid receptors in human endocrine pancreas.","date":"2007","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/18092149","citation_count":158,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21467997","id":"PMC_21467997","title":"GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils.","date":"2011","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21467997","citation_count":158,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16204352","id":"PMC_16204352","title":"Cannabinoid receptor type 2 gene is associated with human osteoporosis.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16204352","citation_count":157,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22763024","id":"PMC_22763024","title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients.","date":"2012","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/22763024","citation_count":154,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12153574","id":"PMC_12153574","title":"Presence and regulation of the endocannabinoid system in human dendritic cells.","date":"2002","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12153574","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8679694","id":"PMC_8679694","title":"Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.","date":"1996","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8679694","citation_count":150,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16563625","id":"PMC_16563625","title":"CB2 cannabinoid receptor mediation of antinociception.","date":"2006","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/16563625","citation_count":146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18334483","id":"PMC_18334483","title":"The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18334483","citation_count":145,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17068343","id":"PMC_17068343","title":"Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17068343","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45590,"output_tokens":5892,"usd":0.112575},"stage2":{"model":"claude-opus-4-6","input_tokens":9493,"output_tokens":4393,"usd":0.235935},"total_usd":0.837618,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":61302,"output_tokens":12208,"usd":0.183513},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":16611,"output_tokens":4827,"usd":0.305595}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CB2 receptor is coupled to G-proteins and mediates inhibition of adenylyl cyclase (Gi-coupled signaling), with binding properties and effector systems characterized pharmacologically.\",\n      \"method\": \"Radioligand binding assays, in vitro effector/cAMP assays\",\n      \"journal\": \"Pharmacology & therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — foundational pharmacological characterization replicated across many labs, >1000 citations\",\n      \"pmids\": [\"9336020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CB2-selective agonist HU-308 inhibits forskolin-stimulated cAMP production in CB2-transfected cells but not CB1-transfected cells, confirming Gi-coupled cAMP inhibition as a primary CB2 effector mechanism and demonstrating CB2-mediated peripheral anti-inflammatory and analgesic effects blocked by CB2 antagonist SR-144528.\",\n      \"method\": \"cAMP assay in transfected cells; in vivo pharmacology with selective antagonists\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted in transfected cells plus in vivo antagonist validation; >450 citations\",\n      \"pmids\": [\"10588688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Rat CB2 receptor, when stably expressed in CHO cells, activates mitogen-activated protein kinase (MAPK/ERK), establishing MAPK activation as a downstream signaling pathway of CB2.\",\n      \"method\": \"Stable expression in CHO cells, MAPK activation assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay in heterologous expression system, single study\",\n      \"pmids\": [\"12084572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CB2 receptor activation via arachidonylcyclopropylamide (ACPA) increases microglial cell migration through a pertussis toxin-sensitive (Gi/o) mechanism, blocked by CB2 antagonists SR144528 and cannabinol, demonstrating CB2-mediated regulation of microglial migration.\",\n      \"method\": \"Migration assay with BV-2 microglial cells, pertussis toxin pretreatment, selective antagonists\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional cell migration assay with pharmacological dissection, single lab\",\n      \"pmids\": [\"12921861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CB2 receptor expressed in osteoblasts, osteocytes, and osteoclasts regulates bone mass; CB2-deficient mice show accelerated age-related trabecular bone loss and increased osteoclast number; CB2-specific agonist inhibits osteoclast precursor proliferation and RANKL expression in osteoblasts/stromal cells and attenuates ovariectomy-induced bone loss.\",\n      \"method\": \"CB2 knockout mouse model, bone histomorphometry, in vitro osteoclastogenesis assay, pharmacological agonist studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological rescue with defined cellular phenotypes; >420 citations\",\n      \"pmids\": [\"16407142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CB2 receptor activation promotes mouse neural stem/progenitor cell proliferation through a phosphoinositide-3-kinase (PI3K)/Akt signaling pathway, demonstrated by the CB2-selective agonist JWH-056 increasing neurosphere formation and BrdU incorporation, which was blocked by CB2 antagonist SR-144528 and PI3K/Akt inhibitor BML-257.\",\n      \"method\": \"Neurosphere formation assay, BrdU incorporation, selective antagonists and PI3K inhibitors\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional proliferation assay with pharmacological dissection, single lab\",\n      \"pmids\": [\"17328768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In mouse spermatogonia, CB2 receptor activation by the selective agonist JWH133 induces ERK1/2 MAPK phosphorylation and promotes meiotic progression, with 2-arachidonoylglycerol (2-AG) acting as the autocrine endocannabinoid signal during spermatogenesis.\",\n      \"method\": \"Purified germ cell fractions, primary spermatogonia cultures, western blot for phospho-ERK1/2, flow cytometry for meiotic markers\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct signaling assay in primary cells with selective agonist, single lab\",\n      \"pmids\": [\"19541620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB2 receptor promotes neural progenitor cell proliferation via activation of the PI3K/Akt/mTORC1 pathway, which inhibits p27Kip1, established using selective agonist HU-308, CB2 antagonist SR144528, mTORC1 inhibitor rapamycin, and CB2-deficient mice.\",\n      \"method\": \"HiB5 NP cells, brain organotypic cultures, in vivo adult hippocampal NPs; pharmacological inhibitors, CB2 KO mice, ribosomal S6 phosphorylation assays, BrdU incorporation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pharmacological, genetic, in vitro/in vivo) from single study with strong mechanistic dissection\",\n      \"pmids\": [\"22102284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB2 receptor in osteoblasts targets a Gi protein-cyclin D1 mitogenic axis: CB2 activation stimulates ERK1/2 phosphorylation and de novo Mapkapk2 synthesis, which then enhances CREB transcriptional activity and cyclin D1 mRNA expression; this pathway is inhibited by pertussis toxin (confirming Gi coupling), MEK-ERK inhibitors, and Mapkapk2 siRNA.\",\n      \"method\": \"MC3T3 E1 and calvarial osteoblast cultures, pertussis toxin, MEK inhibitors PD098059/U0126, Mapkapk2 siRNA, western blot, RT-PCR\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including siRNA knockdown and pharmacological inhibitors defining the signaling cascade\",\n      \"pmids\": [\"20803555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB1 and CB2 receptors form functional heteromers in rat brain (pineal gland, nucleus accumbens, globus pallidus) and transfected neuronal cells; within CB1-CB2 heteromers, co-activation results in negative cross-talk in Akt phosphorylation and neurite outgrowth, and bidirectional cross-antagonism (CB1 antagonist blocks CB2 agonist effects and vice versa).\",\n      \"method\": \"BRET/FRET biophysical assays, co-immunoprecipitation, neuronal cell model, Akt phosphorylation assay, neurite outgrowth assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biophysical and biochemical methods plus functional signaling assays; replicated in native tissue and transfected cells\",\n      \"pmids\": [\"22532560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB2 receptor activation by trans-caryophyllene (TC) protects against ischemic injury through activation of the AMPK/CREB signaling pathway and increased BDNF expression; TC failed to alter Akt or ERK activity, and protection was abolished by selective AMPK and CREB inhibitors and by the CB2 antagonist AM630.\",\n      \"method\": \"Rat cortical neuron/glia mixed cultures, OGD/R model, western blot for phospho-AMPK/CREB, pharmacological inhibitors, in vivo MCAO model\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological tools and functional readouts in vitro and in vivo, single lab\",\n      \"pmids\": [\"23414569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPR55 and CB2 receptors form heteromers in HEK293 cells (confirmed by co-immunoprecipitation and BRET); heteromerization modulates signaling such that ERK1/2 MAPK activation is potentiated while GPR55-mediated transcription factor activation (NFAT, NF-κB, CRE) is reduced, and CB2 receptor-mediated signaling is also altered by GPR55 co-expression.\",\n      \"method\": \"Co-immunoprecipitation, BRET assays, label-free dynamic mass redistribution, ERK1/2 activation, gene reporter assays in HEK293 cells\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods for heteromer detection and functional consequences\",\n      \"pmids\": [\"25048571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CB2 and GPR55 receptors form heteromers in cancer cells with unique signaling properties; modulation of these CB2-GPR55 heteromers can modify the antitumoral activity of cannabinoids in vivo.\",\n      \"method\": \"Co-immunoprecipitation, BRET, in vivo tumor models, cancer cell signaling assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical methods with in vivo validation, single lab\",\n      \"pmids\": [\"24942731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CB2 receptors localize to endolysosomes as well as the plasma membrane; intracellular CB2 receptors couple to Gq protein upon activation by intracellular agonists and elicit Ca2+ release from IP3-sensitive and acidic-like stores, whereas extracellular 2-AG and WIN55,212-2 (but not anandamide) trigger delayed Gq-mediated Ca2+ responses via plasmalemmal CB2.\",\n      \"method\": \"Calcium imaging in CB2-expressing U2OS cells, intracellular microinjection of agonists, selective CB2 antagonist AM630, morphological and functional colocalization with endolysosomes\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional imaging with intracellular vs extracellular drug administration plus organelle localization, single lab\",\n      \"pmids\": [\"25033246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CB2 receptor physically interacts with HER2 (co-immunoprecipitation, proximity ligation assay, colocalization in cancer cells); HER2 upregulates CB2 expression via ELK1 transcription factor activation through the ERK cascade, and increased CB2 expression in turn activates HER2 pro-oncogenic signaling at the level of c-SRC tyrosine kinase.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, colocalization; si/shRNA knockdown; CB2 overexpression; MMTV-neu/CB2-KO mouse model; western blot for ELK1, ERK, c-SRC\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (Co-IP, PLA, genetic KO in vivo, RNAi) establishing a novel signaling axis\",\n      \"pmids\": [\"25855725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB2 receptor modulates retinal axon guidance via a PKA-dependent mechanism requiring the netrin-1 receptor DCC (Deleted in Colorectal Cancer); cnr2-/- mice show abnormal eye-specific segregation of retinal projections in the dorsal lateral geniculate nucleus.\",\n      \"method\": \"In vitro growth cone morphology assays, in vivo retinogeniculate projection analysis in CB2 KO mice, pharmacological manipulation, PKA inhibitors\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo experiments with genetic KO and pharmacological tools, single lab\",\n      \"pmids\": [\"23951024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CB2 receptors are functionally expressed in VTA dopamine neurons; electrophysiological studies in single dissociated neurons show that CB2 receptor activation by JWH133 inhibits VTA dopamine neuronal firing; local CB2 activation in nucleus accumbens inhibits cocaine-enhanced extracellular dopamine and cocaine self-administration, blocked by CB2 antagonist AM630.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, single-cell electrophysiology, in vivo microdialysis, self-administration paradigm in rats\",\n      \"journal\": \"Addiction biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — electrophysiology plus in vivo pharmacology with antagonist validation, multiple methods\",\n      \"pmids\": [\"26833913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Electroacupuncture inhibits NLRP3 inflammasome activation in macrophages through CB2 receptors; CB2 receptor stimulation directly inhibits NLRP3 inflammasome activation in a macrophage cell line, and EA effects on NLRP3 were largely attenuated in CB2 receptor knockout mice.\",\n      \"method\": \"CB2 KO mice, caspase-1 activity assay, western blot for NLRP3 components, immunofluorescence, in vitro macrophage CB2 stimulation\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO validation plus in vitro mechanistic studies, single lab\",\n      \"pmids\": [\"28782714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Agonist-induced CXCR4/CB2 heterodimerization inhibits CXCR4-mediated cell migration and invasion through inhibition of the Gα13/RhoA signaling axis, reducing RhoA-mediated cytoskeletal rearrangement and integrin α5 expression in prostate cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, Boyden chamber migration/invasion assays, western blot for Gα13/RhoA, cytoskeletal imaging, adhesion assays in prostate cancer cells\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional and biochemical assays defining the signaling mechanism, single lab\",\n      \"pmids\": [\"29330286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of human CB2 in complex with antagonist AM10257 determined at 2.8 Å resolution; structural analysis and mutagenesis revealed the molecular basis of CB2 activation, ligand selectivity over CB1, and identified a ligand with opposing functional profiles (CB2 antagonism vs. CB1 agonism) due to differences in binding pose; the extracellular portion of antagonist-bound CB2 shares conformational similarity with agonist-bound CB1.\",\n      \"method\": \"X-ray crystallography at 2.8 Å, site-directed mutagenesis, molecular docking, pharmacological characterization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation; >300 citations, foundational structural study\",\n      \"pmids\": [\"30639103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Phytocannabinoids suppress innate immune responses to oral pathogens through a CB2/PI3K signaling axis; CB2 gene silencing and pharmacological inhibition of PI3K abrogated the immunosuppressive effects, and CBD failed to suppress P. gingivalis-induced innate immune markers in CB2-/- mice.\",\n      \"method\": \"siRNA gene silencing, pharmaceutical PI3K inhibition, CB2-/- mice, in vivo oral infection model, cytokine measurements\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological validation in vitro and in vivo, single lab\",\n      \"pmids\": [\"31681262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CNR2/CB2 receptor binds to JAK1 and inhibits downstream STAT signaling in T cells, thereby impairing tumor-specific T cell function and suppressing anti-tumor immunity; identified using a FLAG-tagged Cnr2 knock-in mouse model and co-immunoprecipitation.\",\n      \"method\": \"FLAG-tagged Cnr2 knock-in mouse, co-immunoprecipitation, STAT signaling assays, CB2 knockout/knockdown in T cells, tumor models\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — knock-in model with Co-IP identifying JAK1 as a binding partner plus functional STAT signaling readout and in vivo tumor models\",\n      \"pmids\": [\"35383142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CB2 receptors expressed specifically in peripheral sensory neurons (advillin-positive) are necessary for both CB2 agonist-mediated antinociception and sparing of morphine tolerance in anti-retroviral toxic neuropathy; conditional knockout of CB2 in sensory neurons abolished antinociceptive effects of structurally distinct CB2 agonists AM1710 and LY2828360.\",\n      \"method\": \"advillinCre/+;CB2f/f conditional knockout mice, nociceptive behavioral assays, morphine tolerance paradigm, cytokine mRNA quantification\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO approach with cell-type specificity and multiple behavioral and molecular readouts\",\n      \"pmids\": [\"36417942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of CB2R bound to selective agonists (LEI-102, APD371, HU308, CP55,940) and site-directed mutagenesis identify key residues for CB2R activation; highly lipophilic agonists (HU308, endocannabinoids) access the binding pocket through a membrane channel between TM1-TM7, while more polar ligands enter via the extracellular space.\",\n      \"method\": \"Cryo-EM structural determination, site-directed mutagenesis, binding kinetics assays, in vivo pharmacological validation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures with mutagenesis and functional validation; identifies molecular mechanism of selective CB2R activation\",\n      \"pmids\": [\"36922494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CB2 receptor forms homodimers; a homobivalent ligand simultaneously occupies the orthosteric site of one protomer and a membrane-oriented pocket between TM1 and TM7 of the partner protomer, enhancing homodimerization and resulting in increased potency in Gi-mediated signaling and enhanced β-arrestin recruitment.\",\n      \"method\": \"Computational modeling, pharmacological assays, Gi-mediated signaling assays, β-arrestin recruitment assays\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — computational and pharmacological evidence for homodimer modulation with functional signaling readouts, single study\",\n      \"pmids\": [\"39179054\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CNR2/CB2 is a Gi-coupled GPCR that inhibits adenylyl cyclase/cAMP, activates ERK1/2 MAPK and PI3K/Akt/mTORC1 signaling, and can also signal via Gq-mediated Ca2+ release from intracellular stores; its crystal and cryo-EM structures reveal ligand entry through both extracellular and membrane (TM1-TM7) routes; it forms functional heteromers with CB1, GPR55, CXCR4, and HER2 that create unique signaling platforms, and directly binds JAK1 to inhibit STAT signaling in T cells; CB2 expressed in peripheral sensory neurons, osteoblasts/osteoclasts, dopamine neurons, neural progenitors, and immune cells mediates distinct tissue-specific functions including antinociception, bone remodeling, neurogenesis, and immune modulation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"CNR2 (CB2) was cloned from macrophages in the marginal zone of spleen; it encodes a G-protein-coupled receptor for cannabinoids that is expressed in the periphery (macrophages/spleen) but not in the brain, establishing it as the peripheral cannabinoid receptor distinct from the CNS-expressed CB1.\",\n      \"method\": \"Molecular cloning, receptor expression in heterologous cells, radioligand binding\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper, foundational, >3900 citations, multiple orthogonal methods\",\n      \"pmids\": [\"7689702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CB2 mRNA is expressed at 10–100-fold higher levels in immune tissues than CB1, with rank order B-cells > NK cells >> monocytes > PMNs > T8 > T4 cells; CB2 protein was confirmed by immunohistology restricted to B-lymphocyte-enriched mantle zones of secondary follicles in tonsil.\",\n      \"method\": \"Quantitative RT-PCR, Northern blot, immunohistochemistry on human immune tissues and leukocyte subpopulations\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, foundational distribution paper\",\n      \"pmids\": [\"7556170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Mouse CB2 (mCB2) was cloned from a splenocyte cDNA library; both hCB2 and mCB2 mediate agonist-stimulated inhibition of forskolin-induced cAMP production in stably transfected CHO cells, demonstrating Gi-coupled adenylyl cyclase inhibition as the primary effector mechanism.\",\n      \"method\": \"Molecular cloning, cAMP assay in transfected CHO cells, radioligand binding\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro functional reconstitution with cloned receptor, replicated across species\",\n      \"pmids\": [\"8679694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CB2 is coupled to Gi-proteins; its effector systems include inhibition of adenylyl cyclase and modulation of ion channels; CB2 is present in peripheral tissues and immune cells but absent from the CNS under normal conditions.\",\n      \"method\": \"Pharmacological review integrating binding assays, functional effector studies, and tissue distribution data\",\n      \"journal\": \"Pharmacology & therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive integration of multiple experimental datasets, >1100 citations\",\n      \"pmids\": [\"9336020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CB2 receptors are most abundantly expressed in peripheral blood and tonsillar B cells among leukocytes; CB2 expression is downregulated during B-cell differentiation (lowest in germinal-center centroblasts); CD40-mediated activation upregulates CB2 within 24 h; CB2 agonist CP55,940 enhances CD40-mediated B-cell proliferation in a CB2-antagonist-reversible manner.\",\n      \"method\": \"Anti-CB2 immunopurified antibody staining, dual-color confocal microscopy, RT-PCR, Western blot, flow cytometry, proliferation assays with selective antagonist SR144528\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, functional pharmacological validation\",\n      \"pmids\": [\"9808554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HU-308, a CB2-selective agonist (Ki = 22.7 nM at CB2, >10 µM at CB1), inhibits forskolin-stimulated cAMP production in CB2-transfected cells but not CB1-transfected cells, and produces anti-inflammatory and peripheral analgesic effects blocked by CB2 antagonist SR-144528 but not CB1 antagonist SR-141716A, confirming peripheral CB2-mediated signaling.\",\n      \"method\": \"Radioligand binding, cAMP assay in transfected cells, in vivo pharmacology with selective antagonists\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro receptor assays plus in vivo pharmacological validation with selective antagonists\",\n      \"pmids\": [\"10588688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Rat CB2 (rCB2) was cloned and found to be 410 amino acids, with a longer C-terminus than human or mouse CB2; rCB2 activates MAP kinase (ERK1/2) when stably expressed in CHO cells, establishing MAPK activation as a CB2 signaling output.\",\n      \"method\": \"cDNA library cloning, CHO cell stable expression, MAPK phosphorylation assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, receptor cloning with functional MAPK readout\",\n      \"pmids\": [\"12084572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CB2 cannabinoid receptor was functionally expressed in Pichia pastoris with retained pharmacological binding profile; purified receptor was confirmed by MALDI/TOF and ESI mass spectrometry, providing the first purified preparation for structural characterization.\",\n      \"method\": \"Heterologous expression in yeast, radioligand binding, metal-chelating chromatography purification, mass spectrometry peptide sequencing\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reconstitution of purified receptor, single lab\",\n      \"pmids\": [\"12460775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CB2 receptor activation with selective agonist JWH-133 induced growth inhibition of skin tumors in vivo accompanied by increased apoptosis and impaired tumor vascularization (decreased VEGF, placental growth factor, angiopoietin 2 expression) and abrogation of EGF-R function.\",\n      \"method\": \"In vivo tumor model (nude mice), immunohistochemistry, RT-PCR for angiogenic factors, pharmacological manipulation with selective CB2 agonist\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic/pharmacological model with defined molecular readouts\",\n      \"pmids\": [\"12511587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CB2 receptors on microglial cells mediate blockade of β-amyloid-induced microglial activation and neurotoxicity; cannabinoids including the selective CB2 agonist JWH-133 blocked Aβ-induced microglial activation (mitochondrial activity, TNF-α release, cell morphology) and abrogated microglia-mediated neurotoxicity in cortical co-cultures.\",\n      \"method\": \"Primary microglial cultures, rat cortical co-cultures, selective CB2 agonist, TNF-α ELISA, mitochondrial activity assay, intracerebroventricular WIN55,212-2 in rats\",\n      \"journal\": \"Journal of Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo approaches, replicated with selective CB2 agonist\",\n      \"pmids\": [\"15728830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Fatty acid amide hydrolase (FAAH) and CB2 receptors are selectively and abundantly expressed in neuritic plaque-associated astrocytes and microglia, respectively, in Alzheimer's disease brain, while CB1 expression remains unchanged, suggesting CB2 upregulation in neuroinflammation.\",\n      \"method\": \"Immunohistochemical analysis with specific polyclonal antibodies on postmortem AD and control brain sections\",\n      \"journal\": \"Journal of Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct protein localization by immunohistochemistry, well-controlled with specific antibodies\",\n      \"pmids\": [\"14657172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CB2 receptor (but not CB1) mediates ACPA-induced microglial cell migration via Gi/o protein-coupled signaling; this effect is blocked by CB2 antagonists (SR144528, cannabinol) and abn-CBD receptor antagonists, but not by CB1 antagonist SR141716A.\",\n      \"method\": \"BV-2 microglial cell migration assay, pertussis toxin pretreatment, selective receptor antagonists\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection with selective antagonists in functional migration assay\",\n      \"pmids\": [\"12921861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CB2 receptors are upregulated in hepatic myofibroblasts/activated stellate cells in cirrhotic liver (absent from normal liver); CB2 activation triggers antifibrogenic effects including growth inhibition (via cyclooxygenase-2) and apoptosis (via oxidative stress); CB2-/- mice develop enhanced liver fibrosis after CCl4 treatment.\",\n      \"method\": \"Immunohistochemistry on human liver biopsies, RT-PCR, GTPγS assays, culture assays with COX-2 inhibitors, ROS measurement, CB2 knockout mouse model\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including human tissue, cell culture, and knockout mouse, replicated across models\",\n      \"pmids\": [\"15765409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CB2-deficient mice exhibit markedly accelerated age-related trabecular bone loss, increased osteoclast number, and decreased osteoblast precursors; a CB2-specific agonist inhibits proliferation of osteoclast precursors, reduces RANKL expression in bone marrow-derived osteoblasts/stromal cells, and attenuates ovariectomy-induced bone loss, demonstrating CB2 is essential for normal bone mass maintenance.\",\n      \"method\": \"CB2 knockout mice, histomorphometry, bone marrow colony assays, pharmacological treatment with CB2-selective agonist, ovariectomy model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus pharmacological rescue, multiple cellular and in vivo readouts\",\n      \"pmids\": [\"16407142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Alkylamides from Echinacea (dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide A1 and dodeca-2E,4E-dienoic acid isobutylamide A2) bind CB2 with Ki ~60 nM (>25-fold selective over CB1) and elevate total intracellular Ca2+ in CB2-positive HL60 cells via CB2, blocked by CB2 antagonist SR144528; they also upregulate constitutive IL-6 in a CB2-dependent manner.\",\n      \"method\": \"Radioligand displacement assay ([3H]CP-55,940), Ca2+ imaging in CB2+ vs CB2- cells, selective antagonist, IL-6 measurement\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — binding confirmed by displacement, functional Ca2+ and cytokine readout with genetic/pharmacological controls\",\n      \"pmids\": [\"16547349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CB2 activation with the selective agonist JWH133 protects against hepatic ischemia/reperfusion injury by decreasing inflammatory cell infiltration, tissue TNF-α, MIP-1α, MIP-2, lipid peroxidation, and ICAM-1 expression; CB2-/- mice develop increased I/R-induced tissue damage, confirming CB2-mediated hepatoprotection.\",\n      \"method\": \"In vivo mouse I/R model, CB2-/- mice, JWH133 pharmacological treatment, cytokine ELISA, lipid peroxidation assay, ICAM-1/VCAM-1 expression, neutrophil adhesion assay\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic approaches in vivo with defined molecular endpoints\",\n      \"pmids\": [\"17327359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CB2 receptor activation attenuates TNF-α-induced NF-κB and RhoA activation, upregulation of ICAM-1 and VCAM-1, MCP-1 expression, transendothelial monocyte migration, and monocyte-endothelial adhesion in human coronary artery endothelial cells, identifying CB2 as a regulator of endothelial inflammatory signaling.\",\n      \"method\": \"Human coronary artery endothelial cell cultures, Western blot, RT-PCR, NF-κB luciferase reporter, transendothelial migration assay, monocyte adhesion assay, in vivo aorta experiments\",\n      \"journal\": \"American Journal of Physiology. Heart and Circulatory Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro and in vivo endpoints with CB2-selective pharmacology\",\n      \"pmids\": [\"17660390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CB2 receptor inverse agonist Sch.414319 downregulates phosphorylation of the monocyte-specific actin-bundling protein L-plastin in human monocytes, suggesting a mechanism for CB2-mediated inhibition of immune cell motility.\",\n      \"method\": \"Biochemical profiling across 45 enzymes and 80 GPCRs/ion channels, protein phosphorylation analysis in human monocytes, in vivo immune cell mobility assay\",\n      \"journal\": \"British Journal of Pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — selective compound, phosphoproteomics, in vivo validation; single lab\",\n      \"pmids\": [\"17906679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB2 receptor activation (JWH133) mediates antinociception in wild-type mice, with significantly reduced effects in CB2-/- mice, while morphine antinociception was unaffected in CB2-/- mice, genetically confirming that AM1241 produces antinociception specifically through CB2 receptors.\",\n      \"method\": \"CB2 knockout mice, thermal nociception assay, pharmacological challenge with selective agonist AM1241 and WIN55,212-2\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with pharmacological validation, clean phenotypic readout\",\n      \"pmids\": [\"16563625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB2 receptor is expressed in mouse male germ cells; the selective CB2 agonist JWH133 induces ERK1/2 MAPK phosphorylation in spermatogonia and promotes their progression toward meiosis (increased SCP3-positive cells and meiotic prophase gene expression), with 2-AG acting as the autocrine endocannabinoid signal.\",\n      \"method\": \"Purified germ cell fractions, primary spermatogonia cultures, selective CB2 agonist treatment, ERK1/2 Western blot, BrdU incorporation, meiotic marker immunostaining\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with selective pharmacology and cell-specific readouts\",\n      \"pmids\": [\"19541620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB2 receptor gene (CNR2) has two promoters transcribing distinct isoforms: CB2A (testis/brain-predominant) and CB2B (spleen/peripheral-predominant); mouse CB2A expression in cerebellum is upregulated by the mixed CB receptor agonist WIN55212-2.\",\n      \"method\": \"Genomic mapping, RT-PCR with isoform-specific primers, Northern blot, drug treatment of mice\",\n      \"journal\": \"Genes, Brain, and Behavior\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genomic and transcript analysis across species with pharmacological manipulation\",\n      \"pmids\": [\"19496827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GPR55 and CB2 receptors physically interact in human neutrophils; GPR55 activation augments CB2-mediated migration while inhibiting CB2-mediated degranulation and ROS production; mechanistically, GPR55 and CB2 interfere with each other's signaling at the level of small GTPases Rac2 and Cdc42.\",\n      \"method\": \"Human neutrophils and HL60 cells, co-immunoprecipitation, BRET, migration assays, degranulation assay, ROS production assay, dominant-negative small GTPase constructs\",\n      \"journal\": \"Cell Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus BRET plus functional mechanistic dissection of GTPase signaling\",\n      \"pmids\": [\"21467997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB2 receptor mRNA and protein are expressed in rat brain (including ventral midbrain); mice with reduced CB2 function due to the R63 allele of rs2501432 show lower cAMP responses in transfected CHO cells; CB2 antagonist AM630 exacerbates MK-801- or methamphetamine-induced prepulse inhibition deficits in mice.\",\n      \"method\": \"RT-PCR, in situ hybridization, CHO cell functional assay (cAMP), human genetic association, pharmacological behavioral test\",\n      \"journal\": \"Biological Psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — functional cell assay for variant plus pharmacological behavioral readout; single lab\",\n      \"pmids\": [\"19931854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB2 receptor-selective agonist HU-308 activates the PI3K/Akt/mTORC1 pathway in hippocampal neural progenitor cells, inhibiting p27Kip1 and inducing proliferation; this effect is blocked by CB2 antagonist SR144528, PI3K/Akt/mTORC1 inhibitors, and absent in CB2-deficient mouse neural progenitors.\",\n      \"method\": \"HiB5 NP cell cultures, brain organotypic cultures, CB2-/- mice, Western blot for p-Akt/p-S6/p27, BrdU incorporation, pharmacological inhibitors, CB2-deficient NP cells\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches in vitro and in vivo with genetic and pharmacological controls\",\n      \"pmids\": [\"22102284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB2 receptors promote mouse neural stem/progenitor cell proliferation via phosphoinositide-3-kinase/Akt signaling; selective CB1 and CB2 antagonists block basal neurosphere proliferation suggesting endocannabinoid tone; PI3K inhibitor BML-257 blocks cannabinoid agonist-stimulated proliferation.\",\n      \"method\": \"Neurosphere culture, BrdU incorporation, selective CB1/CB2 agonists and antagonists, PI3K inhibitor\",\n      \"journal\": \"European Journal of Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection with functional readout; single lab\",\n      \"pmids\": [\"17328768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB2 receptor in osteoblasts activates a Gi protein–Erk1/2–MAPKAPK2–CREB–cyclin D1 mitogenic axis; CB2 agonist-induced osteoblast proliferation is blocked by pertussis toxin, MEK-Erk1/2 inhibitors (PD098059, U0126), and Mapkapk2 siRNA, identifying the signaling sequence for CB2-driven bone formation.\",\n      \"method\": \"MC3T3-E1 and primary calvarial osteoblast cultures, pertussis toxin, selective kinase inhibitors, siRNA knockdown, Western blot, CREB reporter, cyclin D1 RT-PCR\",\n      \"journal\": \"Journal of Bone and Mineral Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitors and siRNA defining a sequential signaling pathway, replicated in two cell models\",\n      \"pmids\": [\"20803555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB2 and CB1 receptors form functional heteromers in rat brain (pineal gland, nucleus accumbens, globus pallidus) and in transfected neuronal cells; co-activation of both receptors within CB1–CB2 heteromers produces negative cross-talk in Akt phosphorylation and neurite outgrowth; heteromers exhibit bidirectional cross-antagonism where CB1 antagonists block CB2 agonist effects and vice versa.\",\n      \"method\": \"BRET, FRET, co-immunoprecipitation in transfected neuronal cells and rat brain tissue, Akt phosphorylation assay, neurite outgrowth measurement\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biophysical (BRET/FRET) plus biochemical (co-IP) plus functional (Akt, neurite) in both heterologous and native brain tissue\",\n      \"pmids\": [\"22532560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB2 receptor activation by trans-caryophyllene ameliorates ischemic neuronal injury through AMPK/CREB signaling: TC enhanced phosphorylation of AMPK and CREB and increased BDNF expression; AMPK and CREB inhibitors abolished neuroprotection; TC had no effect on Akt or ERK activity, distinguishing this pathway from canonical CB2 signaling.\",\n      \"method\": \"Rat cortical neuron/glia cultures, OGD/reoxygenation model, Western blot, selective inhibitors of AMPK and CREB, in vivo MCAo model with infarct measurement\",\n      \"journal\": \"American Journal of Pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective pharmacological pathway dissection in vitro and in vivo with AM630 reversal controls\",\n      \"pmids\": [\"23414569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Agonist-induced formation of CB2–GPR55 heteromers in cancer cells produces unique signaling: ERK1/2-MAPK activation is potentiated while GPR55-mediated transcription factor activation (NFAT, NF-κB, CRE) is reduced; CB2 co-expression modifies GPR55 signaling and vice versa; modulation of these heteromers alters antitumoral activity of cannabinoids in vivo.\",\n      \"method\": \"Co-immunoprecipitation, BRET in HEK293 cells, label-free real-time assays (Epic DMR, CellKey impedance), ERK1/2-MAPK phosphorylation, gene reporter assays, in vivo tumor model\",\n      \"journal\": \"British Journal of Pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — BRET plus co-IP plus multiple functional signaling assays plus in vivo validation\",\n      \"pmids\": [\"25048571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Agonist-induced CB2–GPR55 heteromers in cancer cells exhibit unique signaling properties distinct from either receptor alone; in vivo, modulation of CB2–GPR55 heteromers modifies antitumoral efficacy of cannabinoids.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, ERK signaling assays, in vivo tumor model, shRNA modulation of CB2\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical approaches plus in vivo validation\",\n      \"pmids\": [\"24942731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CB2 receptors localize to endolysosomes as well as the plasma membrane; intracellular CB2 activation by microinjected agonists (2-AG, anandamide, WIN55,212-2) triggers fast, transient Ca2+ elevation from inositol 1,4,5-trisphosphate-sensitive and acidic-like Ca2+ stores via Gq coupling, whereas extracellular anandamide is ineffective; plasmalemmal CB2 activation by 2-AG and WIN55,212-2 triggers delayed, Gq-mediated Ca2+ responses.\",\n      \"method\": \"Ca2+ imaging in CB2-expressing U2OS cells, intracellular microinjection, selective CB2 antagonist AM630, Gq inhibitors, endolysosomal markers\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — novel subcellular localization with functional consequence, intracellular vs extracellular agonist delivery, multiple controls\",\n      \"pmids\": [\"25033246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HER2 upregulates CB2 expression via the transcription factor ELK1 through the ERK cascade; elevated CB2 activates HER2 pro-oncogenic signaling at the level of the tyrosine kinase c-SRC; HER2 and CB2 form heteromers in breast cancer cells; genetic inactivation of CB2 impairs tumor generation and progression in MMTV-neu mice.\",\n      \"method\": \"siRNA/shRNA knockdown, overexpression, co-immunoprecipitation, proximity ligation assay, colocalization, ELK1 reporter, MMTV-neu CB2-/- mouse model, human tumor tissue arrays\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical approaches plus genetic mouse model plus human tissue validation\",\n      \"pmids\": [\"25855725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CB2 receptor mediates antinociception in a CB2-/- validated model; AM1241 antinociception is absent in CB2-/- mice but morphine antinociception is normal, confirming specificity; CB2 knockout mice exhibited robust ddC-induced neuropathy (replicated in antiretroviral model).\",\n      \"method\": \"CB2 knockout mice, thermal nociception and mechanical allodynia assays, selective CB2 agonists\",\n      \"journal\": \"Pain (replicated in 2022 paper PMID:35001054 and earlier PMID:16563625)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout validated across multiple studies and models\",\n      \"pmids\": [\"16563625\", \"35001054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Functional CB2 receptors are expressed in VTA dopamine neurons in rats; CB2 agonist JWH133 inhibits VTA DA neuronal firing in single dissociated neurons; local CB2 agonist in nucleus accumbens inhibits cocaine-enhanced extracellular DA and intravenous cocaine self-administration, blocked by CB2 antagonist AM630.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, single-cell electrophysiology, in vivo microdialysis, i.v. cocaine self-administration with intra-NAcc microinjection\",\n      \"journal\": \"Addiction Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — electrophysiology plus in vivo microdialysis plus behavioral pharmacology with site-specific and receptor-selective approaches\",\n      \"pmids\": [\"26833913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"B-lymphoid transcription factors PAX5 and IKZF1 transcriptionally repress CNR2 as part of a metabolic gatekeeper program; CNR2 is identified as a central effector restricting glucose and energy supply in B-lymphoid cells; pharmacological CNR2 agonism synergizes with glucocorticoids to induce energy crisis and cell death in pre-B ALL.\",\n      \"method\": \"ChIP-seq, RNA-seq, CRISPR/Cas9 screen of PAX5/IKZF1 transcriptional targets, metabolic analysis, pharmacological CB2 agonism in pre-B ALL mouse model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — CRISPR screen plus ChIP-seq plus metabolic assays plus in vivo validation\",\n      \"pmids\": [\"28792788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Agonist co-activation of CXCR4 and CB2 induces heterodimer formation on cancer cell membranes, decreasing Gα13 and RhoA protein levels, abrogating RhoA-mediated cytoskeletal rearrangement, reducing integrin α5 (ITGA5) expression, and inhibiting cell migration, invasion, and adhesion to extracellular matrices.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, RhoA activation assay, migration/invasion/adhesion assays, siRNA knockdown in prostate cancer cells\",\n      \"journal\": \"Molecular Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — co-IP plus functional signaling and migration readouts; single lab\",\n      \"pmids\": [\"29330286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of human CB2 in complex with antagonist AM10257 at 2.8 Å resolution; the structure reveals a binding pose distinct from CB1 but extracellular conformation similar to agonist-bound CB1, explaining AM10257's unexpected opposing functional profile (CB2 antagonism vs CB1 agonism); mutagenesis and molecular docking identify molecular basis for CB1/CB2 functional selectivity and provide insight into CB2 activation mechanism.\",\n      \"method\": \"X-ray crystallography at 2.8 Å, site-directed mutagenesis, molecular docking, functional pharmacology\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis plus functional validation, published in Cell\",\n      \"pmids\": [\"30639103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cannabichromene (CBC) is a selective CB2 receptor agonist: it activates CB2 but not CB1 to produce cell hyperpolarization in AtT20 cells, an effect blocked by AM630 and sensitive to pertussis toxin (Gi coupling); CBC induces loss of cell-surface CB2 receptors and receptor desensitization, indicating recruitment of regulatory mechanisms.\",\n      \"method\": \"AtT20 cells stably expressing HA-tagged CB1 or CB2, membrane potential assay, receptor internalization assay, pertussis toxin treatment, selective antagonist AM630\",\n      \"journal\": \"British Journal of Pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional electrophysiology-based assay with Gi coupling demonstrated by pertussis toxin sensitivity, receptor internalization assay\",\n      \"pmids\": [\"31368508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cannabinoids suppress innate immunity to oral pathogens via a CB2/PI3K axis: THC, CBD, and CBN suppress P. gingivalis-induced cytokine production in human innate cells through CB2 and PI3K; CB2-/- mice lack this suppression in an oral infection model in vivo.\",\n      \"method\": \"Human monocyte cultures, siRNA gene silencing, pharmacological PI3K inhibition, CB2-/- mouse oral infection model, ELISA cytokine measurement\",\n      \"journal\": \"Frontiers in Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA, pharmacological, and genetic knockout validation of CB2/PI3K pathway\",\n      \"pmids\": [\"31681262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CNR2 binds to JAK1 and inhibits downstream STAT signaling in T cells; THC and anandamide impair tumor-specific T cell function through CNR2; discovered using a FLAG-tagged Cnr2 knock-in mouse model and co-immunoprecipitation.\",\n      \"method\": \"FLAG-tagged Cnr2 knock-in mouse model, co-immunoprecipitation of CNR2 with JAK1, STAT phosphorylation assay, tumor-specific T cell functional assay, in vivo tumor models\",\n      \"journal\": \"Signal Transduction and Targeted Therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — endogenous tagged protein co-IP in knock-in mice plus functional signaling readout; novel binding partner identification\",\n      \"pmids\": [\"35383142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CB2 localized specifically to peripheral sensory neurons (advillin+ cells) mediates both antinociceptive efficacy of CB2 agonists and sparing of morphine tolerance in a ddC-induced neuropathy model; advillinCre/+;CB2f/f conditional knockout mice lack CB2 agonist antinociception and morphine tolerance sparing, while retaining ddC-induced neuropathy and morphine antinociception.\",\n      \"method\": \"Conditional knockout mice (advillinCre/+;CB2f/f), mechanical allodynia and cold allodynia assays, morphine tolerance protocol, proinflammatory cytokine mRNA measurement\",\n      \"journal\": \"Pharmacological Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific conditional knockout with multiple behavioral and molecular readouts\",\n      \"pmids\": [\"36417942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CB2 expressed in epidermal keratinocytes, Langerhans cells, dendritic cells in dermis, and Merkel cells mediates suppression of chemotherapy-induced peripheral neuropathic nociception; Langerhans cells are dynamically increased in epidermis after paclitaxel treatment; intraplantar CB2 agonist AM1710 elevates IL-10 mRNA in lumbar spinal cord.\",\n      \"method\": \"CB2-GFP BAC reporter mice, anti-GFP immunolabeling, co-expression with cell-type markers, intraplantar drug administration, mechanical/cold allodynia assays, spinal cord cytokine mRNA\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct cell-type localization by reporter mouse plus pharmacological functional validation\",\n      \"pmids\": [\"35001054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of CB2 in complex with selective agonists (LEI-102, APD371, HU308, CP55,940) identify key residues for CB2 activation; highly lipophilic agonists (HU308, endocannabinoids) access the binding pocket via a membrane channel in TM1-TM7, while more polar agonists (LEI-102, APD371, CP55,940) do not, revealing that lipophilicity governs the route of CB2 engagement.\",\n      \"method\": \"Cryo-EM structural determination, binding kinetics, site-directed mutagenesis, molecular modeling, oral efficacy in chemotherapy-induced nephropathy model\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures with mutagenesis and functional validation, multiple ligands studied\",\n      \"pmids\": [\"36922494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CB2 receptor forms homodimers; a homobivalent ligand simultaneously occupying the orthosteric site of one CB2 protomer and a membrane-oriented allosteric pocket (between TM1 and TM7) of the partner protomer locks the homodimer, increasing potency of Gi-mediated signaling and enhancing β-arrestin recruitment.\",\n      \"method\": \"Computational docking, pharmacological assays (cAMP/Gi signaling, β-arrestin recruitment), bivalent ligand design with 14-methylene linker\",\n      \"journal\": \"Pharmacological Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — computational plus pharmacological functional assays; single lab, no structural validation of dimer\",\n      \"pmids\": [\"39179054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB2 receptor mRNA and protein are expressed in dopaminergic neurons of the VTA in mice; CB2 receptors are predominantly located on post-synaptic elements in rodent brain as determined by electron microscopy; CB2-Rs are modulated in brain following exposure to stressors and abused drugs.\",\n      \"method\": \"RT-PCR, immunoblotting, immunohistochemistry, transmission electron microscopy, in situ hybridization, hippocampal cultures, antisense oligonucleotide injection\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct EM-based subcellular localization with functional behavioral follow-up\",\n      \"pmids\": [\"18286196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB2 receptor controls myeloid progenitor cell trafficking toward inflamed spinal cord in EAE; CB2-/- mice show exacerbated disease with increased myeloid progenitor recruitment, T-lymphocyte infiltration, and microglial activation; CB2 activation reduces EAE symptoms through modulation of CCL2, CCL3, CCL5 chemokines and CCR1, CCR2 receptors.\",\n      \"method\": \"CB2-/- mouse EAE model, bone marrow transfer, selective CB2 agonist pharmacology, flow cytometry, RT-PCR for chemokines/receptors, histological analysis\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus bone marrow transfer plus pharmacological activation with mechanistic chemokine pathway dissection\",\n      \"pmids\": [\"18334483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB2 receptor activation inhibits macrophage ROS production via Rap1 activation; CB1 promotes pro-inflammatory ROS and p38-MAPK phosphorylation in macrophages, while CB2 activates Rap1 to negatively regulate CB1-stimulated ROS, TNF-α, and MCP-1 production; dominant-negative Rap1 enhanced CB1-dependent ROS.\",\n      \"method\": \"Selective expression of CB1 or CB2 in peritoneal macrophages, flow cytometry for ROS, p38-MAPK Western blot, pull-down assay for Rap1 activation, dominant-negative Rap1 construct\",\n      \"journal\": \"Cardiovascular Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — selective receptor expression plus pull-down assay for Rap1 plus dominant-negative construct, clean mechanistic dissection\",\n      \"pmids\": [\"19596672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CB2 receptor protects against balloon-induced neointima formation; CB2 activation (JWH133) reduces intimal nuclei, smooth muscle cells, macrophages, and proliferating cells; CB2-/- mice develop increased intima formation with elevated macrophage adhesion, migration, and smooth muscle cell proliferation, and elevated CCR1, CCR5, and CCL2 mRNA in CB2-/- macrophages.\",\n      \"method\": \"CB2-/- mice, pharmacological CB2 activation, carotid balloon injury model, bone marrow-derived macrophage adhesion/migration assays, smooth muscle cell proliferation assay, RT-PCR for adhesion molecules and chemokines\",\n      \"journal\": \"American Journal of Physiology. Heart and Circulatory Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus pharmacological activation plus in vitro cellular mechanism\",\n      \"pmids\": [\"22227125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB2 receptor modulates axon guidance in the retino-thalamic pathway; CB2R-induced growth cone morphological changes are PKA-dependent and require the netrin-1 receptor DCC (Deleted in Colorectal Cancer); cnr2-/- mice exhibit abnormal eye-specific segregation of retinal projections in the dorsal lateral geniculate nucleus.\",\n      \"method\": \"In vitro retinal axon assays, in vivo cnr2-/- mouse model, pharmacological CB2 manipulation, PKA inhibitor, immunofluorescence for DCC\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout phenotype plus in vitro mechanistic dissection (PKA dependence, DCC requirement)\",\n      \"pmids\": [\"23951024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CB2 receptor expression is increased in hippocampal neurons bearing accumulated TAU in a TAU-dependent manner; CB2 ablation in mice protects from neurodegeneration induced by hTAUP301L overexpression, as shown by preserved cognitive behavior, synaptic plasticity, and reduced insoluble TAU aggregates; CB2 upregulation is confirmed in postmortem Alzheimer's disease brain samples.\",\n      \"method\": \"AAV-TAU mouse models, CB2-/- genetic knockout, gene expression analysis, immunofluorescence, behavioral tests, synaptic plasticity measurement, Western blot for TAU aggregates, human AD postmortem brain\",\n      \"journal\": \"Acta Neuropathologica Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with behavioral and molecular phenotypes, validated in human tissue; single lab\",\n      \"pmids\": [\"34001284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CB2 receptor stimulation (JWH133) inhibits NLRP3 inflammasome activation in inflamed skin macrophages; CB2 knockout mice show attenuated EA effects on NLRP3 inflammasomes; in vitro CB2 stimulation in macrophage cell lines directly inhibits NLRP3 inflammasome activation, defining CB2 as a negative regulator of NLRP3 inflammasome.\",\n      \"method\": \"CFA-induced inflammatory pain rat model, electroacupuncture, CB2-/- mice, caspase-1 activity assay, Western blot, immunofluorescence, in vitro macrophage CB2 stimulation\",\n      \"journal\": \"Brain, Behavior, and Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout validation plus in vitro mechanism; single lab\",\n      \"pmids\": [\"28782714\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CNR2 (CB2) is a Gi-protein-coupled receptor canonically expressed in immune tissues and peripheral organs (and more recently confirmed in brain neurons and glia) that, upon activation by endocannabinoids or synthetic agonists, inhibits adenylyl cyclase, activates ERK1/2-MAPK and PI3K/Akt/mTORC1 pathways, recruits β-arrestin, activates Rap1 to suppress ROS, inhibits NLRP3 inflammasome activation, and (from endolysosomal localization) couples to Gq to release Ca2+; CB2 forms heteromers with CB1, GPR55, CXCR4, and HER2 that create distinct signaling platforms, and its structural basis for ligand binding and activation has been established by crystal structure and cryo-EM studies revealing both orthosteric and membrane-channel access routes for agonists.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CNR2 encodes cannabinoid receptor 2 (CB2), a Gi/o-coupled GPCR that functions as a central mediator of endocannabinoid signaling in immune cells, bone, peripheral sensory neurons, neural progenitors, and dopaminergic circuits. CB2 inhibits adenylyl cyclase via Gi coupling and activates ERK1/2 MAPK, PI3K/Akt/mTORC1, and AMPK/CREB pathways in a cell-type-dependent manner, and can also signal through Gq-mediated Ca²⁺ release from intracellular endolysosomal stores [PMID:9336020, PMID:12084572, PMID:22102284, PMID:25033246]. CB2 forms functionally distinct heteromers with CB1, GPR55, CXCR4, and HER2 that remodel downstream signaling — including negative cross-talk in Akt phosphorylation, altered ERK responses, and inhibition of RhoA-mediated migration — and directly binds JAK1 to suppress STAT signaling and anti-tumor T cell immunity [PMID:22532560, PMID:25048571, PMID:29330286, PMID:35383142]. Crystal and cryo-EM structures reveal dual ligand-entry routes — an extracellular path for polar agonists and a membrane channel between TM1 and TM7 for lipophilic ligands — and CB2 homodimerization can be exploited by bivalent ligands to enhance Gi signaling and β-arrestin recruitment [PMID:30639103, PMID:36922494, PMID:39179054].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that CB2 is a Gi-coupled receptor that inhibits adenylyl cyclase resolved the primary effector mechanism of the second cannabinoid receptor, distinguishing it from CB1 in tissue distribution while sharing core signal transduction.\",\n      \"evidence\": \"Radioligand binding and cAMP inhibition assays with pharmacological characterization\",\n      \"pmids\": [\"9336020\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascades beyond cAMP not yet mapped\", \"Endogenous ligand selectivity between CB1 and CB2 not fully delineated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that the CB2-selective agonist HU-308 inhibited cAMP only in CB2-transfected cells and produced anti-inflammatory/analgesic effects blockable by CB2 antagonist established CB2 as a druggable target with peripheral anti-inflammatory functions.\",\n      \"evidence\": \"cAMP assays in CB1- vs CB2-transfected cells; in vivo pharmacology with SR-144528 antagonist\",\n      \"pmids\": [\"10588688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling pathways beyond cAMP not explored\", \"Cell types mediating in vivo analgesic effects not identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of ERK/MAPK activation as a CB2 downstream pathway expanded the signaling repertoire beyond cAMP inhibition, suggesting proliferative and differentiation-related functions.\",\n      \"evidence\": \"Stable CB2 expression in CHO cells with MAPK activation assay\",\n      \"pmids\": [\"12084572\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream intermediates between Gi and ERK not defined\", \"Physiological relevance in native cell types not shown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showing that CB2 activation drives Gi/o-dependent microglial migration established CB2 as a chemotactic regulator in neuroimmune cells, extending its immune role to the CNS.\",\n      \"evidence\": \"BV-2 microglial migration assay with pertussis toxin sensitivity and CB2 antagonists\",\n      \"pmids\": [\"12921861\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream migration effectors (Rho GTPases, integrins) not mapped\", \"In vivo relevance to neuroinflammation not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that CB2-knockout mice exhibit accelerated age-related bone loss and that CB2 agonism restrains osteoclastogenesis and RANKL expression established CB2 as a physiological regulator of bone remodeling.\",\n      \"evidence\": \"CB2 KO mouse bone histomorphometry; in vitro osteoclastogenesis; pharmacological rescue of ovariectomy-induced bone loss\",\n      \"pmids\": [\"16407142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling cascade in osteoblasts not dissected\", \"Relative contribution of osteoblast vs osteoclast CB2 not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linking CB2 to neural progenitor proliferation via PI3K/Akt signaling revealed a neurogenic function and a second major signaling arm beyond Gi-cAMP-ERK.\",\n      \"evidence\": \"Neurosphere formation and BrdU assays with CB2 agonist JWH-056, antagonist SR-144528, and PI3K inhibitor\",\n      \"pmids\": [\"17328768\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Akt substrates mediating proliferation not identified\", \"In vivo adult neurogenesis phenotype not confirmed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Three concurrent advances defined tissue-specific signaling cascades: CB2 drives neural progenitor proliferation via PI3K/Akt/mTORC1-mediated p27Kip1 inhibition, osteoblast mitogenesis via Gi-ERK-Mapkapk2-CREB-cyclin D1, and CB2-mediated ERK activation in spermatogonia promotes meiotic entry — demonstrating that CB2 couples to distinct effector pathways depending on cellular context.\",\n      \"evidence\": \"Multiple orthogonal approaches: CB2 KO mice, mTORC1 inhibitor rapamycin, Mapkapk2 siRNA, pertussis toxin, MEK inhibitors; primary spermatogonia with phospho-ERK1/2 western blots\",\n      \"pmids\": [\"22102284\", \"20803555\", \"19541620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanisms determining G-protein selectivity in different cell types unknown\", \"Relative contribution of β-arrestin vs G-protein signaling not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Biophysical detection of CB1-CB2 heteromers in native brain tissue with bidirectional cross-antagonism and negative Akt cross-talk established that CB2 signaling is fundamentally altered by receptor-receptor interactions, adding combinatorial complexity to endocannabinoid signaling.\",\n      \"evidence\": \"BRET/FRET, co-IP in rat pineal gland and nucleus accumbens; Akt and neurite outgrowth assays in neuronal cells\",\n      \"pmids\": [\"22532560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of heteromer formation in vivo unknown\", \"Downstream effectors unique to heteromer vs homodimer not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two studies expanded CB2's functional repertoire: CB2 activates AMPK/CREB/BDNF signaling for neuroprotection independently of Akt or ERK, and CB2 modulates retinal axon guidance via PKA/DCC — revealing signaling diversity beyond canonical Gi/ERK/PI3K cascades.\",\n      \"evidence\": \"OGD/R neuronal model with AMPK/CREB inhibitors and AM630; retinal growth cone assays and retinogeniculate projection analysis in CB2 KO mice with PKA inhibitors\",\n      \"pmids\": [\"23414569\", \"23951024\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CB2 activates AMPK independently of Akt remains unclear\", \"PKA activation mechanism downstream of Gi-coupled CB2 not reconciled\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery of CB2-GPR55 heteromers with altered ERK potentiation and reduced NFAT/NF-κB signaling, and demonstration that CB2 localizes to endolysosomes where it couples to Gq to release intracellular Ca²⁺, expanded the spatial and combinatorial dimensions of CB2 signaling.\",\n      \"evidence\": \"Co-IP, BRET, and ERK/gene reporter assays for GPR55-CB2 in HEK293 and cancer cells; calcium imaging with intracellular agonist microinjection and endolysosomal colocalization in U2OS cells\",\n      \"pmids\": [\"25048571\", \"24942731\", \"25033246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endolysosomal CB2-Gq signaling occurs in primary immune cells unknown\", \"In vivo relevance of CB2-GPR55 heteromers in tumors not fully established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of a physical CB2-HER2 interaction with reciprocal positive regulation — HER2 upregulates CB2 via ELK1/ERK and CB2 activates HER2/c-SRC — revealed an unexpected feedforward oncogenic loop linking endocannabinoid and receptor tyrosine kinase signaling.\",\n      \"evidence\": \"Co-IP, proximity ligation assay, siRNA/shRNA, CB2-KO/MMTV-neu mouse model, western blots\",\n      \"pmids\": [\"25855725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the CB2-HER2 complex forms in non-cancer tissues unknown\", \"Therapeutic strategy to disrupt the feedforward loop not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Electrophysiological proof that CB2 is functionally expressed in VTA dopamine neurons and inhibits their firing, together with in vivo evidence that local CB2 activation suppresses cocaine-evoked dopamine release and self-administration, established a direct CB2-dopamine modulatory axis.\",\n      \"evidence\": \"Single dissociated VTA neuron electrophysiology, in vivo microdialysis, self-administration paradigm with JWH133 and AM630 in rats\",\n      \"pmids\": [\"26833913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of CB2-mediated inhibition of dopamine neuron firing not dissected at channel level\", \"Whether CB2 and CB1 co-express in same VTA neurons and form heteromers not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstration that CXCR4-CB2 heterodimerization inhibits CXCR4-driven cancer cell migration by blocking Gα13/RhoA signaling showed that CB2 can function as an endogenous brake on chemokine receptor-mediated invasion through heteromer formation.\",\n      \"evidence\": \"Co-IP, Boyden chamber assays, Gα13/RhoA western blots, cytoskeletal imaging in prostate cancer cells\",\n      \"pmids\": [\"29330286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CXCR4-CB2 heteromers form in immune cells in vivo not tested\", \"Structural basis of heteromer interface unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The 2.8 Å crystal structure of CB2 bound to antagonist AM10257 provided the first atomic-level view of CB2, explaining CB1/CB2 selectivity through distinct binding-pocket residues and revealing that antagonist-bound CB2 paradoxically resembles agonist-bound CB1 at the extracellular face.\",\n      \"evidence\": \"X-ray crystallography, site-directed mutagenesis, molecular docking, pharmacological characterization\",\n      \"pmids\": [\"30639103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state structure with Gi complex not available at this time\", \"Mechanism of biased agonism not structurally resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Two discoveries resolved long-standing questions about cell-type-specific CB2 functions: CB2 in peripheral sensory neurons is necessary and sufficient for antinociception and morphine-tolerance sparing, and CB2 directly binds JAK1 to suppress STAT signaling in T cells, thereby dampening anti-tumor immunity.\",\n      \"evidence\": \"Advillin-Cre conditional CB2 KO mice with nociceptive assays; FLAG-Cnr2 knock-in mice with JAK1 co-IP and STAT assays in tumor models\",\n      \"pmids\": [\"36417942\", \"35383142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CB2-JAK1 interaction is direct or scaffolded remains unclear\", \"Signaling intermediates between sensory neuron CB2 and morphine tolerance not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM structures of CB2 bound to four distinct agonists identified dual ligand-entry routes — an extracellular path for polar ligands and a TM1-TM7 membrane channel for lipophilic endocannabinoids — providing a structural framework for selective drug design.\",\n      \"evidence\": \"Cryo-EM structure determination, site-directed mutagenesis, binding kinetics, in vivo pharmacology\",\n      \"pmids\": [\"36922494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state structure with full Gi heterotrimer not yet reported\", \"Whether dual entry routes exist for other lipid GPCRs not explored\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Evidence that a homobivalent ligand bridges two CB2 protomers — occupying the orthosteric site of one and the TM1-TM7 membrane pocket of another — demonstrated functional homodimerization and showed that dimer engagement enhances both Gi signaling potency and β-arrestin recruitment.\",\n      \"evidence\": \"Computational modeling, Gi-mediated signaling and β-arrestin recruitment assays\",\n      \"pmids\": [\"39179054\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Homodimer structure not experimentally determined\", \"In vivo relevance of CB2 homodimer pharmacology not tested\", \"Computational dimer model awaits cryo-EM or crystallographic validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CB2 heteromer interfaces (CB1, GPR55, CXCR4, HER2), the molecular determinants that switch CB2 coupling from Gi to Gq in different subcellular compartments, and how CB2-JAK1 binding is regulated and whether it operates independently of G-protein signaling.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No heteromer interface structure available\", \"Mechanism of Gi-to-Gq switch at endolysosomes vs plasma membrane undefined\", \"Whether CB2-JAK1 interaction is G-protein-dependent or -independent not tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 19, 23]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 11, 14, 18, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 13, 19, 23]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 5, 7, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 17, 20, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 5, 7, 8, 14]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [15, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 6, 15]}\n    ],\n    \"complexes\": [\n      \"CB1-CB2 heteromer\",\n      \"CB2-GPR55 heteromer\",\n      \"CB2-CXCR4 heteromer\",\n      \"CB2-HER2 complex\"\n    ],\n    \"partners\": [\n      \"CNR1\",\n      \"GPR55\",\n      \"CXCR4\",\n      \"ERBB2\",\n      \"JAK1\",\n      \"MAPKAPK2\",\n      \"DCC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CNR2 (CB2) is a Gi/o-protein-coupled cannabinoid receptor predominantly expressed in immune cells (B cells, macrophages, microglia) and peripheral tissues—with regulated expression also in CNS neurons—that transduces endocannabinoid and phytocannabinoid signals into anti-inflammatory, immunomodulatory, and metabolic outcomes [PMID:7689702, PMID:7556170, PMID:26833913]. Upon agonist binding, CB2 inhibits adenylyl cyclase, activates ERK1/2-MAPK, PI3K/Akt/mTORC1, AMPK/CREB, and Rap1 pathways, recruits β-arrestin, and—from endolysosomal compartments—couples to Gq to mobilize intracellular Ca²⁺, while negatively regulating NF-κB, RhoA, NLRP3 inflammasome, and JAK1-STAT signaling [PMID:8679694, PMID:22102284, PMID:25033246, PMID:19596672, PMID:28782714, PMID:35383142]. CB2 forms functionally distinct heteromers with CB1, GPR55, CXCR4, and HER2 that remodel downstream signaling selectivity, and its structural basis—including orthosteric and lipophilicity-gated membrane-channel agonist entry routes—has been defined by crystal and cryo-EM structures [PMID:22532560, PMID:25048571, PMID:30639103, PMID:36922494]. Genetic loss of CB2 in mice results in accelerated bone loss, exacerbated hepatic fibrosis, enhanced neuroinflammation, and altered pain sensitivity, establishing CB2 as a physiological brake on inflammation, bone resorption, and nociceptive signaling [PMID:16407142, PMID:15765409, PMID:18334483, PMID:36417942].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Cloning of CNR2 from spleen macrophages established the existence of a second cannabinoid receptor expressed in the periphery and molecularly distinct from the CNS-expressed CB1, resolving whether a single receptor mediated all cannabinoid effects.\",\n      \"evidence\": \"Molecular cloning from macrophage cDNA, radioligand binding in heterologous cells\",\n      \"pmids\": [\"7689702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Post-translational modifications uncharacterized\", \"No structural information\", \"CNS expression not assessed beyond Northern blot\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstration that CB2 inhibits forskolin-stimulated cAMP production via Gi coupling in transfected cells identified the primary effector mechanism and confirmed functional conservation across species.\",\n      \"evidence\": \"cAMP assays in CHO cells stably expressing human or mouse CB2\",\n      \"pmids\": [\"8679694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling beyond adenylyl cyclase unknown\", \"No information on G-protein subtype specificity\", \"No endogenous cell system tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapping of CB2 expression to B-cell subsets and demonstration that CB2 agonism enhances CD40-driven B-cell proliferation provided the first functional link between CB2 signaling and adaptive immune cell biology.\",\n      \"evidence\": \"Confocal microscopy, flow cytometry, proliferation assays with CB2 antagonist reversal in tonsillar B cells\",\n      \"pmids\": [\"9808554\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates between CB2 and proliferative machinery undefined\", \"No in vivo B-cell functional data\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Cloning of rat CB2 and demonstration that it activates ERK1/2-MAPK expanded the known CB2 effector repertoire beyond adenylyl cyclase inhibition, suggesting mitogenic signaling capacity.\",\n      \"evidence\": \"Stable CHO cell expression, MAPK phosphorylation assay\",\n      \"pmids\": [\"12084572\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pathway intermediates between Gi and ERK not mapped\", \"Relevance to endogenous immune cells not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"CB2 was shown to mediate microglial migration, suppress Aβ-induced microglial neurotoxicity, and become upregulated on microglia in Alzheimer's disease brain, overturning the view that CB2 is absent from the CNS and identifying it as a neuroinflammatory regulator.\",\n      \"evidence\": \"Primary microglia migration assays, cortical co-cultures with selective CB2 agonist JWH-133, immunohistochemistry on postmortem AD brain\",\n      \"pmids\": [\"15728830\", \"14657172\", \"12921861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether microglial CB2 is neuroprotective or disease-promoting in vivo remained unclear\", \"Mechanism of CB2 transcriptional upregulation in neuroinflammation unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"CB2-knockout mice developed exacerbated hepatic fibrosis after toxic injury, and CB2 activation triggered apoptosis of hepatic myofibroblasts, establishing CB2 as a physiological antifibrogenic brake in liver.\",\n      \"evidence\": \"CB2−/− mice with CCl4 fibrosis model, immunohistochemistry on human cirrhotic liver, ROS and COX-2 assays\",\n      \"pmids\": [\"15765409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional program of CB2 in stellate cells not defined\", \"Whether CB2 agonists can reverse established fibrosis not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstration that CB2-knockout mice exhibit accelerated age-related bone loss and that CB2 agonism inhibits osteoclast precursor proliferation and RANKL expression revealed CB2 as essential for bone mass homeostasis.\",\n      \"evidence\": \"CB2−/− mice, histomorphometry, ovariectomy rescue with CB2 agonist, bone marrow colony assays\",\n      \"pmids\": [\"16407142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates in osteoclast precursors not mapped\", \"Human genetic association with osteoporosis not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"CB2 activation suppressed TNF-α-induced NF-κB, ICAM-1/VCAM-1, and monocyte transendothelial migration in coronary endothelial cells, and protected against hepatic ischemia/reperfusion injury in vivo, mechanistically linking CB2 to vascular inflammatory control.\",\n      \"evidence\": \"Human coronary artery endothelial cells, NF-κB reporter, CB2−/− I/R model, cytokine ELISAs\",\n      \"pmids\": [\"17660390\", \"17327359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CB2 signaling events linking Gi to NF-κB suppression not fully resolved\", \"Receptor desensitization kinetics in endothelium unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Detection of CB2 mRNA and protein on VTA dopamine neurons by electron microscopy, and demonstration that CB2 deficiency worsens autoimmune encephalomyelitis via enhanced myeloid progenitor trafficking, established CB2 function in both the CNS and in autoimmune cell migration control.\",\n      \"evidence\": \"Transmission EM in rodent brain, CB2−/− EAE model, bone marrow transfer, chemokine profiling\",\n      \"pmids\": [\"18286196\", \"18334483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Electrophysiological consequence of neuronal CB2 not yet shown at single-cell level\", \"Mechanism of CB2-dependent chemokine regulation not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"CB2 was found to activate Rap1 in macrophages to suppress CB1-stimulated ROS and proinflammatory mediators, providing a molecular mechanism for CB2's anti-inflammatory role via small GTPase cross-talk; separately, GPR55–CB2 physical interaction was demonstrated to modulate neutrophil migration and degranulation through Rac2/Cdc42.\",\n      \"evidence\": \"Rap1 pull-down with dominant-negative constructs in macrophages; BRET and co-IP for GPR55–CB2 in neutrophils/HL60 cells\",\n      \"pmids\": [\"19596672\", \"21467997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Rap1 axis operates in non-macrophage contexts unknown\", \"GPR55–CB2 heteromer stoichiometry and structural basis undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"CB2 was shown to activate PI3K/Akt/mTORC1 to promote neural progenitor proliferation and Gi–ERK1/2–MAPKAPK2–CREB–cyclin D1 for osteoblast mitogenesis, mapping cell-type-specific signaling cascades downstream of CB2; CB1–CB2 heteromers were identified in brain with bidirectional cross-antagonism on Akt and neurite outgrowth.\",\n      \"evidence\": \"CB2−/− neural progenitors, PI3K/Akt inhibitors, siRNA of MAPKAPK2, BRET/FRET/co-IP in neuronal cells and rat brain\",\n      \"pmids\": [\"22102284\", \"20803555\", \"22532560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heteromer stoichiometry not determined\", \"In vivo consequence of CB1–CB2 heteromerization on behavior unknown\", \"Whether mTORC1 axis contributes to tumor biology not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that CB2 localizes to endolysosomes and, upon intracellular agonist delivery, couples to Gq to release Ca²⁺ from IP3-sensitive and acidic stores demonstrated a previously unrecognized compartment-dependent signaling mode distinct from canonical plasma membrane Gi signaling.\",\n      \"evidence\": \"Microinjection of agonists into CB2-expressing U2OS cells, Ca²⁺ imaging, Gq inhibitors, endolysosomal markers\",\n      \"pmids\": [\"25033246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological ligand delivery route to endolysosomal CB2 unclear\", \"Whether endolysosomal CB2 signaling occurs in immune cells not tested\", \"Structural basis for Gq coupling not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"HER2 was found to transcriptionally upregulate CB2 via ELK1–ERK and to form HER2–CB2 heteromers that activate c-SRC pro-oncogenic signaling; CB2 genetic inactivation impaired HER2-driven mammary tumorigenesis, revealing CB2 as a co-opted oncogenic effector in breast cancer.\",\n      \"evidence\": \"siRNA/shRNA, co-IP, PLA, ELK1 reporter, MMTV-neu CB2−/− mouse model, human tumor tissue arrays\",\n      \"pmids\": [\"25855725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HER2–CB2 heteromer is druggable unknown\", \"Downstream transcriptional program of CB2–c-SRC not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Electrophysiological recording from single dissociated VTA DA neurons confirmed functional CB2 receptors inhibit neuronal firing, and intra-accumbal CB2 agonism reduced cocaine-enhanced dopamine and self-administration, establishing a direct neuronal function for CB2 in reward circuitry.\",\n      \"evidence\": \"Single-cell electrophysiology, in vivo microdialysis, intra-NAcc microinjection with CB2 antagonist reversal\",\n      \"pmids\": [\"26833913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Postsynaptic vs presynaptic CB2 mechanism in DA neurons not resolved\", \"Whether CB2 modulates other addictive substances through same circuit not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"CB2 was identified as a central effector of the PAX5/IKZF1 metabolic gatekeeper program in B-lymphoid cells, where it restricts glucose and energy supply; pharmacological CB2 agonism synergized with glucocorticoids to induce metabolic crisis in pre-B ALL, redefining CB2 as a metabolic checkpoint.\",\n      \"evidence\": \"CRISPR/Cas9 screen, ChIP-seq, RNA-seq, metabolic flux analysis, pre-B ALL mouse model\",\n      \"pmids\": [\"28792788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Metabolic effectors downstream of CB2 (glucose transporter regulation) not fully mapped\", \"Whether this mechanism operates outside B-lymphoid lineage unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The 2.8 Å crystal structure of CB2 bound to antagonist AM10257 revealed a ligand-binding pose distinct from CB1 and explained divergent functional selectivity between the two receptors, providing the first atomic-resolution template for CB2 drug design.\",\n      \"evidence\": \"X-ray crystallography, site-directed mutagenesis, molecular docking, functional pharmacology\",\n      \"pmids\": [\"30639103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state structure not yet available at this point\", \"Mechanism of agonist-induced conformational change not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"CNR2 was found to physically bind JAK1 and suppress JAK-STAT signaling in T cells, with THC and anandamide impairing tumor-specific T cell responses through this axis, uncovering a non-canonical CB2 signaling mechanism relevant to tumor immune evasion.\",\n      \"evidence\": \"FLAG-Cnr2 knock-in mouse, endogenous co-IP of CNR2–JAK1, STAT phosphorylation, tumor-specific T cell functional assays\",\n      \"pmids\": [\"35383142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CNR2–JAK1 interaction unknown\", \"Whether JAK1 inhibition is Gi-dependent or independent not resolved\", \"Relevance to non-tumor immunity untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Conditional deletion of CB2 from peripheral sensory neurons (advillin+ cells) abolished CB2 agonist antinociception and morphine tolerance sparing, pinpointing the cell type and anatomical site responsible for CB2-mediated pain modulation.\",\n      \"evidence\": \"advillinCre/+;CB2f/f conditional knockout, mechanical and cold allodynia, morphine tolerance protocol\",\n      \"pmids\": [\"36417942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway in sensory neurons mediating antinociception not defined\", \"Whether central CB2 also contributes to pain behavior not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM structures of CB2 with four selective agonists revealed that lipophilic agonists access the binding pocket through a membrane channel between TM1 and TM7, while polar agonists enter from the extracellular face, explaining ligand-dependent pharmacological differences and enabling rational design of pathway-selective agonists.\",\n      \"evidence\": \"Cryo-EM structural determination, binding kinetics, site-directed mutagenesis, molecular modeling\",\n      \"pmids\": [\"36922494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures of CB2 heteromers not available\", \"Whether membrane-channel entry route is physiologically utilized by endocannabinoids requires validation\", \"No structure of CB2 in complex with Gq\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CB2 heteromers (CB1, GPR55, HER2, CXCR4), the mechanism by which endolysosomal CB2 switches from Gi to Gq coupling, the full signaling cascade linking CB2 to JAK1 inhibition, and whether CB2's metabolic gatekeeper role in B-lymphoid cells extends to other immune lineages.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No heteromer structures available\", \"Endolysosomal Gq coupling mechanism unresolved\", \"CNR2–JAK1 structural interface undefined\", \"Metabolic checkpoint function outside B-lineage untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 3, 37]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [39, 50]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 30, 37]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [30]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 6, 23, 25, 26, 30, 46]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 9, 15, 16, 45, 50]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [33, 44]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [13, 48]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [34]}\n    ],\n    \"complexes\": [\n      \"CB1-CB2 heteromer\",\n      \"CB2-GPR55 heteromer\",\n      \"CB2-HER2 heteromer\",\n      \"CB2-CXCR4 heteromer\"\n    ],\n    \"partners\": [\n      \"CNR1\",\n      \"GPR55\",\n      \"ERBB2\",\n      \"CXCR4\",\n      \"JAK1\",\n      \"RAP1A\",\n      \"DCC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}